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Beside 5’-capping and 3’-polyadenylation, splicing is one of the essential steps in the 
processing of most protein-coding genes in higher eukaryotes. It is catalyzed by the 
spliceosome, a large and dynamic RNA-protein molecular machine that encompasses five 
core components, the U1, U2, U4, U5 and U6 snRNPs. For each splicing reaction, a 
spliceosome is assembled anew in a stepwise manner. Spliceosomes must accurately 
recognize each splice site, as a single mistake can result in the production of a non-
functional and potentially toxic protein. The crucial step of exon definition is facilitated by 
the U1 and U2 snRNP during early splicing. Cryo electron microscopy structures of early 
spliceosomal complexes in yeast have shown that the Prp39/Prp42 heterodimer is a 
crucial scaffolding subcomplex. It acts as a hub for multiple protein-protein interactions for 
example the contact between the U1 and the U2 snRNP, indicating that the Prp39/Prp42 
heterodimer is important for the precise spatial positioning of the U1 and U2 snRNPs 
relative to each other. Interestingly there is no homolog for Prp42 in higher eukaryotes. 
PRPF39 is largely unstudied in higher eukaryotes and came to our attention because it is 
alternatively spliced in a differential manner in murine naïve vs. memory T-cells. I could 
show that an alternative exon is included in a differential manner. This can control PRPF39 
expression by NMD in a tissue- and activation-dependent manner in mice and human, 
suggesting a role in adapting splicing efficiency to cell type specific requirements. 
Furthermore, I solved the crystal structure of murine PRPF39 at 3.3 Å resolution. The 
protein is largely α-helical and the structure shows the protein to be organized as a 
homodimer. Dimerization in solution could be confirmed with further biophysical assays. 
The mode of PRPF39 homodimerization is strikingly similar to heterodimerization of Prp39 
and Prp42 in yeast. Structure guided point mutations could completely abolish dimerization 
and by using the monomeric PRPF39 mutants I could show that the monomer has a 
detrimental effect on splicing in vitro. Based on a structural comparison of murine PRPF39 
and the yeast heterodimer, we performed a phylogenetic analysis showing, that organisms 
with a Prp39 homodimer have a substantially shortened U1 snRNA compared to 
organisms with a Prp39/Prp42 heterodimer. Our analysis indicates that a shortened U1 
snRNA accompanied by a PRPF39 homodimer was crucial in the evolutionary 
development of more complex splicing. This observation is unexpected, as fewer splicing 
factors usually mirror lower splicing complexity and not the opposite. 
Taken together, my results reveal the structural and functional implications of murine 
PRPF39 on splicing. The data suggests, that a PRPF39 homodimer acts to substitute the 




complexity of the U1 snRNP may have been crucial in allowing highly complex and 





Spleißen ist neben 5‘-Capping und 3’-Polyadenylierung einer der essenziellen Schritte bei 
der Prozessierung von prä-mRNA in höheren Eukaryoten. Das Spleißen wird vom 
Spleißosom katalysiert, einer großen und dynamischen RNA-Protein-Maschinerie. Das 
Spleißosom umfasst fünf Kernbestandteile: Die U1, U2, U4, U5 und U6 snRNPs. Bei 
jedem Spleißzyklus wird das Spleißosom schrittweise auf dem prä-mRNA Substrat von 
Grund auf neu gebildet. Spleißosome müssen dabei jede Spleißstelle genau erkennen, da 
ein einzelner Fehler zur Produktion von nicht-funktionellem und möglicherweise toxischem 
Protein führen könnte. Während des frühen Spleißens wird der elementare Schritt der 
Exon-Definition durch die U1 und U2 snRNPs ermöglicht. Studien mit 
Kryoelektronenmikroskopie haben bei frühen spleißosomalen Komplexen in Hefe gezeigt, 
dass das Prp39/Prp42 Heterodimer ein essenzieller Faktor in der räumlichen Anordnung 
des U1 snRNP zum U2 snRNPs ist. Des Weiteren ist das Prp39/Prp42 Heterodimer eine 
Interaktionsschnittstelle für viele weitere Proteine, welche das Spleißen beeinflussen 
können. Dabei gibt es interessanterweise in höheren Eukaryoten kein homolog für Prp42. 
PRPF39 ist in höheren Eukaryoten bisher kaum erforscht. Wir sind auf PRPF39 
aufmerksam geworden, weil es in naïven T-zellen und T-Gedächtniszellen aus Mäusen 
unterschiedlich alternativ gespleißt wird. Ich konnte zeigen, dass ein alternatives Exon 
unterschiedlich stark inkludiert wird. Dadurch wird über NMD die PRPF39 Expression in 
einer gewebe- und differenzierungs-spezifischen Art kontrolliert. Dies impliziert eine Rolle 
dieses Spleißereignisses bei der Regulierung der Spleißeffizienz gemäß den 
Anforderungen der Zelle. Des Weiteren habe ich die Struktur von PRPF39 bei einer 
Auflösung von 3.3 A gelöst. Das Protein ist größtenteils α-helikal und liegt als Homodimer 
vor. Weitere biophysikalische Experimente zeigten auch die Dimerisierung in Lösung auf. 
Die Dimerisierungsart ist sehr ähnlich zu der des Hefe Pr39/Prp42 Heterodimers. Durch 
strukturbasierte Punktmutationen konnte ich die Dimerisierung komplett auflösen und 
einen inhibierenden Effekt des Monomers auf das Spleißen zeigen. Basierend auf einem 
Vergleich des Maus-Homodimers und des Hefe-Heterodimers haben wir eine 
phylogenetische Analyse durchgeführt. Diese zeigt, dass Organismen mit einem 
Homodimer im Vergleich zu Organismen mit einem Heterodimer eine stark verkürzte U1 
snRNA haben. Korreliert man diese Daten mit der Spleißkomplexität von Organismen, 
wird deutlich, dass eine kürzere U1 snRNA und ein PRPF39 Homodimer vorteilhaft für 
komplexeres Spleißen sind. Dies entspricht nicht den Erwartungen, da in der Regel 




Zusammenfassend zeigen meine Ergebnisse die strukturellen und funktionellen 
Auswirkungen von PRPF39 auf das Spleißen. Die Daten deuten an, dass das PRPF39 
Homodimer in höheren Eukaryoten das Prp39/Prp42 Heterodimer aus der Hefe 
substituieren kann. Des Weiteren scheint eine reduzierte RNA- und Proteinkomplexität 
des U1 snRNP über viele Spezies hinweg unverzichtbar gewesen zu sein, um 






The cell has a wide molecular repertoire, of which three types of macromolecules stand 
out especially, due to their functions: Deoxyribonucleic acid (DNA), ribonucleic acid (RNA), 
and proteins. The interplay between these macromolecules is essential for life and has 
been described as the central dogma of molecular biology. According to this dogma, our 
genetic information is encoded on our DNA containing the information required to build, 
maintain and propagate organisms. The DNA is then transcribed into RNA which acts as 
a coding intermediate that can then be translated into proteins, the functional final product 
(Crick 1958). This flow of information was originally believed to be unidirectional. However, 
with new scientific findings like the discovery of retroviruses that use RNA as a template 
for DNA synthesis (Temin and Mizutani 1970) or the multiple functions of non-coding RNAs 
this simple picture is no longer enough to satisfy the ever complex interplay of these key 
macromolecules. 
A mature messenger RNA (mRNA) consists of a sequence of nucleotides (nt) that 
correspond to the amino acid sequence in the resulting protein. This is called the coding 
region. The additional sequences on either side of the coding region are called 5’ 
untranslated region (UTR) and 3’ UTR. The UTRs frequently contain regulatory sequences 
that can control the stability, cellular location and translational activity of the transcripts 
(Mayr 2017, Leppek 2018). 
However, a precursor mRNA (pre-mRNA) must undergo several steps of processing 
before it can be exported into the cytoplasm as mature mRNA. Amongst the processing 
steps is the addition of a 7-methylguanosine cap at the 5’ end. The m7G cap (m7GpppN) 
is important for mRNA export into the cytoplasm, initiation of protein synthesis and the 
stabilization of the mRNA (McCracken 1997). In the step of polyadenylation, the transcript 
is cleaved at a specific site and a tail comprised of 100-200 adenosine monophosphate 
residues is added by the poly(A) polymerase (Colgan and Manley 1997). 
The third important step in pre-mRNA processing is called splicing. Most genes in higher 
Eukarya contain additional noncoding sequences interspersed between the coding 
sequences. The noncoding parts are called introns and the coding segments are called 
exons. To allow proper translation the intronic regions need to be excised from the pre-
mRNA under subsequent ligation of the exons (Figure 1). Splicing was first observed in 





Figure 1 Gene expression in eukaryotes. DNA is transcribed to pre-mRNA containing exons (boxes 
and introns (lines). After processing (capping, polyadenylation and splicing) it can be exported into 
the cytoplasm. There translation and protein production is performed by the ribosomes. 
The process of nuclear pre-mRNA splicing is highly conserved from yeast to human and 
can be catalyzed by the spliceosome, a multi megadalton protein RNA machinery. 
However, the level of splicing complexity can vastly vary between different organisms. 
Almost all human genes contain introns. In contrast, Saccharomyces cerevisiae only has 
introns in 4.5 % of its genes (Ivashchenko 2009), furthermore, the yeast introns are 
generally of relatively short size (100-400 nt) with a rather fixed length of approximately 
120 nt.compared to the human introns varying from 100 to 500000 nt (Rowen 2002, Ast 
2004). 
After processing the now mature RNA can be exported into the cytoplasm. Once the 
mRNA has reached the cytoplasm, translation can take place catalyzed by the ribosome, 
a complex apparatus made up of proteins and RNA (Figure 1). 
 
5.1 Alternative splicing 
When analyzing the human genome, it becomes apparent that the number of protein 
coding genes (20,000-25,000) cannot account for the much larger amount of 80,000 to 
120,000 translated protein products (Liang 2000, Yura 2006, Nilsen and Graveley 2010), 
assuming a linear relationship in which one protein results from one gene. This 
discrepancy could possibly be explained by alternative splicing, which occurs in up to 95 
% of all human genes (Nilsen and Graveley 2010) emphasizing the importance of this 




incorporated in a differential manner, to generate several variable mRNA isoforms from a 
single pre-mRNA species (Black 2003). 
With the help of RNA sequencing technologies, we are able to detect a profusion of splice 
variants on RNA level. But up until now, it is only poorly studied to which extent these 
transcripts are actually translated into proteins. Even though we can now find numerous 
alternative splicing events with RNA sequencing, it remains challenging to functionally 
characterize the events, as up until now it is still mostly done individually for each case. 
However, a recent large scale study was performed that showed that isoforms generated 
by alternative splicing have different interaction profiles, with less than 50 % of their 
interaction partners in common (Yang 2016). 
The most common mode of alternative splicing is the exclusion or inclusion of an entire 
exon. In some cases, alternative 3’ or 5’ splice site within exons or introns can be used, 
which can either shorten or lengthen an exon respectively. More rarely, a complete intron 
can be included in the final mRNA. Sometimes a special case of exon skipping is present, 
in which two adjacent exons are included only in a mutually exclusive manner (Keren 
2010). Importantly, not only one alternative splice event can occur in a single transcript, 
but multiple different combinations are possible, even further expanding the plethora of 
possible different isoforms from one gene (Figure 2). 
 
Figure 2 Alternative splicing of pre-mRNA. Five basic types of alternative splicing are included. The 
exons are indicated as boxes and the introns are show as thick lines. The possible splice site usage 




The different mRNA isoforms can give rise to proteins that differ from each other in their 
amino acid sequence, and thus also in their chemical and biological properties. Alternative 
mRNA isoforms however do not always result in different proteins, in some cases inclusion 
of an exon or intron with a premature stop codon can lead to nonsense mediated decay 
(NMD). This is one of the many RNA degradation machineries that ensures that 
mis-spliced mRNA variants are efficiently degraded before they can be translated into 
proteins that could potentially be toxic to the organism. In some cases, an alternative exon 
that harbors a premature stop codon can act as a poison exon controlling the amount of 
protein produced by regulating the alternative splicing of this particular exon (Kervestin 
and Jacobson 2012) (Figure 3).  
 
Figure 3 Nonsense mediated decay. After constitutive splicing RNA is translated into protein (filled 
box). Upon inclusion of an alternative exon with a premature stop codon, the NMD machinery is 
recruited which results in degradation of the pre-mRNA. 
Alternative splicing is known to be an essential switch in gene expression that can 
influence many cellular and developmental processes like sex determination, apoptosis, 
axon guidance, cell excitation and contraction (Black 2003). Because of its importance in 
so many cellular processes, a tight regulation of alternative splicing is necessary to ensure 
the well-being of the organism.  
 
5.2 Regulation of Alternative Splicing 
Splicing can be regulated by cis- and trans-acting factors. Cis-acting factors are 
sequences in the RNA that can bind trans-acting proteins thus regulating splicing by 
enhancing or decreasing specific splice site usage (Figure 4).  
Cis-acting elements can be categorized into four different types depending on their 
location in the pre-mRNA and their effect on splice site usage: exonic splicing silencers 
(ESS), exonic splicing enhancers (ESE), intronic splicing silencers (ISS) and intronic 





Figure 4 Influence of cis- and trans-acting factors during splicing. Trans-acting factors recognize 
and bind to cis-acting elements. Orange T-bars indicate suppression of a particular splice site, and 
pale green arrows promotion. 
The best characterized protein families of the trans-acting factors are the serine/arginine-
rich (SR) proteins and the heterogenous nuclear ribonucleoprotein particles (hnRNPs). 
SR-proteins mostly act as positive regulators of splicing, while hnRNPs are mostly 
negative regulators of splicing (Busch and Hertel 2012, Fu and Ares 2014). 
Alternative splicing is regulated by many different cellular processes and in a development 
and tissue specific manner. For example, cell stage specific splicing was characterized 
during neuronal development (Raj and Blencowe 2015), and in differentiated cells in 
response to cellular signaling and cellular stresses (Biamonti and Caceres 2009, Martinez 
and Lynch 2013) like temperature changes (Preussner 2017), UV-light (Sharma and Lou 
2011) or infections (Shin and Manley 2004). 
 
5.2.1 Tissue Specific Alternative Splicing 
As it is of special relevance to this study, I will focus on regulation of alternative splicing in 
a tissue specific manner. Alternative splicing has been widely implicated in specifying 
tissues. As previously described (chapter 5.2), cis- and trans-acting elements are largely 
responsible for regulation of splicing. However, when looking at splicing in a tissue specific 
manner, it is clear, that the differences of splicing in different tissues of the same organism 
have to be based on trans-acting elements, as the cis-acting environment is the same in 
every cell of an organism. Each cell-type has its own specific composition of SR proteins 
and hnRNPs, with their relative abundance in each tissue determining the respective 
alternative splicing patterns (Chen and Manley 2009). 
In addition, there are some well-known examples for tissue specific expression of proteins, 
most prominently NOVA, RBFOX and ESRPs (Ule 2005, Warzecha 2010, Lovci 2013). A 
genome wide study compared RNA sequencing data from nine different tissues and ten 
different species. (Barbosa-Morais 2012). Overall splicing complexity increased with the 
complexity of the organism. When comparing alternative splicing in different organs and 




species, than between the same organ in different species (Barbosa-Morais 2012). This is 
supported by the fact that the cis-acting environment remains the same in all tissues of an 
organism with only differential expression of trans-acting factors influencing alternative 
splicing. 
 
5.3 The Mechanism of Nuclear pre-mRNA Splicing 
Introns can be classified into four major classes with different splicing mechanisms. 
Transfer RNA (tRNA)/archaeal introns, autocatalytic group I and group II introns and 
spliceosomal introns (Haugen 2005). 
tRNA introns are generally very short (14-160 nt) and can be found in tRNA genes of 
Archaea and Eukarya. The introns do not share any sequence homology, but have very 
conserved locations, mostly at the anticodon stem. tRNA introns are enzymatically excised 
by a cut-and-rejoin mechanism that requires adenosine triphosphate (ATP) an 
endonuclease and a ligase (Calvin and Li 2008). 
Group I splicing introns are also small (250-500 nt) and self-splice using a distinctive two-
step transesterification pathway with a guanosine as a cofactor. This type of splicing can 
be found in bacteria and eukaryotes. Most of the identified type I introns are encountered 
in Eukarya with a special enrichment in plants, algae and fungi (Haugen 2005). 
Like group I introns, group II introns catalyze their own excision, but are phylogenetically 
unrelated to group I introns. Group II introns can be found in some bacteria and organellar 
genomes of plants, fungi, protists and some animals and self-splice in a mechanism 
different from group I introns but similar to the one used by the spliceosome. (Toor 2008, 
Chan 2012). 
Spliceosomal or pre-mRNA introns are excised through a mechanism that is very similar 
to that of the group II introns and are likely to be evolutionarily related to each other (Irimia 
and Roy 2014). The introns are removed, and the exons are ligated in two sequential SN2-
type transesterification reactions (Query 1994, Will and Luhrmann 2011). Introns in pre-
mRNAs are highly variable in size with minimal conservation in their secondary and tertiary 
structure. One of the major challenges during splicing is splice site definition, especially in 
higher eukaryotes, considering the highly variable sequences and lengths of the introns. 
Accurate splice site definition is crucial, as an error in just one nt can be devastating, 
causing a shift in the reading frame resulting in a completely different or no protein product. 
Intron and exon definition is mainly facilitated by short consensus sequences, namely the 




assembly, consensus sequences can be recognized with a subsequent assembly of the 
spliceosome on the pre-mRNA. Comparing yeast and metazoan organisms, some 
differences in the consensus sequences become apparent (Figure 5) (Wahl 2009, Will 
and Luhrmann 2011). In S. cerevisiae, we see a high sequence conservation in the three 
cis-elements with at least 90 % conservation (Spingola 1999). In higher Eukarya, the 
conservation is lower, but a nt pattern is still identifiable. Furthermore, just upstream of the 
3’ splice site lies another highly conserved element of 10-12 nt, the polypyrimidine tract 
(PPT), which is composed of mainly pyrimidines. 
 
Figure 5 Conserved sequence elements found in introns from metazoans and yeast. Exons and 
introns are shown as boxes and lines, respectively. The BP adenosine is highlighted in orange. Y 
and R stand for pyrimidine and purine and the polypyrimidine tract is represented as (Yn) 
In the first step, the oxygen of the 2’ OH group of the BP adenosine performs a nucleophilic 
attack on the phosphodiester bond of the 5’ splice site. As a result of the first 
transesterification reaction, a free 3’ OH group at the 3’ terminal nt of the 5’ exon and a 5’-
2’ phosphodiester bond between the 5’ splice site guanosine and the BP guanosine are 
formed. In the second step, the 3’ OH group of the free 5’ exon attacks the phosphodiester 
bond at the 3’ splice site of the lariat intermediate containing the intron and the downstream 
exon. In this step the 5’ and 3’ exons are joined, and the intron is excised in form of a 
lasso-shaped lariat (Figure 6).  
 
Figure 6 Schematic representation of the two-step mechanism of pre-mRNA splicing. Boxes and 
solid lines represent the exons and introns, respectively. The branch site adenosine is indicated by 
the letter “A” and the phosphate groups by the letter “p” inside a circle. The dotted arrows show the 




The lariat intron is then debranched and typically degraded but can also be a source of 
regulatory RNAs (Carthew and Sontheimer 2009, Voinnet 2009), while the mRNA is 
exported to the cytoplasm for translation (Brow 2002). 
Chemically, the process of splicing seems very simple. But due to the scarce information 
contained in the short consensus sequences, many trans-acting elements are necessary 
for proper splice site selection. Additionally, pre-mRNA folding is required to bring together 
the splice site to allow for accurate splicing. These trans-acting factors are assembled in 
a stepwise manner and form the highly dynamic macromolecular machine called the 
spliceosome. 
 
5.4 The Spliceosome 
The human spliceosome is a highly complex assembly made up of more than 200 
components in humans (Agafonov 2011). In contrast, the yeast system is made up of 
significantly fewer components than the human spliceosome (Fabrizio 2009) and has been 
viewed as a simplified model system that lends itself more willingly to studies on the core 
spliceosome. The major building blocks of the spliceosome are five small nuclear 
ribonucleoproteins (snRNPs). The core components of snRNPs are small nuclear uridine-
rich RNAs (U1, U2, U4, U5 and U6 snRNAs), seven common Sm or Sm-like proteins 
arranged around the snRNA forming a heteroheptameric ring, and a variable number of 
snRNP specific proteins (Will and Luhrmann 2011). The five snRNAs are numbered 
according to their discovery. The U3 snRNP is not part of the spliceosome but involved in 
ribosomal RNA processing. U4 and U6 form a di-snRNP through extensive base-pairing 
of their snRNAs. 
The spliceosome assembles on the pre-mRNA in a stepwise manner for each splicing 
event. However, none of the mentioned particles contains a preformed catalytically active 
center to carry out the two-step splicing reaction. The catalytic center is formed upon 
complex rearrangements of the spliceosome which happens anew for each splicing cycle 
(Figure 7). The canonical assembly observed in all eukaryotes is based on intron 
recognition (Berget 1995). However, in metazoans introns can exceed a length of 250 nt 
by far, and an alternative assembly pathway has been observed in these cases. This 
pathway mainly differs from the cross- intron assembly in the early steps of splicing, where 






Figure 7 Schematic representation of the splicing cycle. For simplicity the ordered interactions of 
the snRNPs (indicated as circles), but not those of the non-snRNP proteins are shown. Exon and 
intron sequences are indicated by boxes and lines respectively. Because the main focus of this 
thesis lies on the U1 snRNP steps involving this particle are highlighted. Adapted from (Wahl 2009). 
The first step of splicing entails the recruitment of the U1 snRNP to the 5’ splice site by 
base pairing of the U1 snRNA with the 5’ splice site. After this, two non-snRNP factors, the 
splicing factor 1 and the U2 auxiliary factor, bind to the BP and the PPT, respectively. 
These initial interactors form the center of the spliceosomal complex E. In the second step, 
the U2 snRNP is incorporated in an ATP-dependent manner. By base pairing of the U2 
snRNA with the BP, splicing factor 1 is displaced leading to complex A formation, also 
called the pre-spliceosome (De Conti 2013). Following this event, the pre-assembled 
U4/U6.U5 tri-snRNP is recruited, resulting in the pre-catalytic complex B. At this point, all 
five snRNPs necessary for splicing are present but need to undergo major compositional 
and conformational rearrangements before the spliceosome becomes catalytically active. 
During this step, the U1 and U4 snRNP are dissociated from the spliceosome respectively 
by the Prp28 and Brr2 helicases, to give rise to the activated spliceosome (Laggerbauer 
1998, Staley and Guthrie 1999). The 5’ end of the U6 snRNA substitutes the U1 snRNA in 
base pairing with the 5’ splice site and an extensive base pairing network is formed 
between the U2 and U6 snRNA bringing the 5’ splice site and BP together for the first 




by the Prp16 helicase, to reposition the splicing intermediates toward each other (Schwer 
and Guthrie 1992). Then the U5 contacts exon nts downstream of the 3’ splice site to align 
the 5’ and 3’ exons to allow the second catalytic step. Finally, the exon junction complex 
is deposited 20 to 25 nt upstream of the exon-exon junction and the mRNA is released in 
form of a messenger ribonucleoprotein complex and transported to the cytoplasm. The 
post-spliceosomal complex is disassembled and all of its components are recycled to take 
part in a new splicing cycle (Martin 2002). 
The mechanism of spliceosome assembly across the exon is slightly different, in which the 
U1 snRNP binds to the 5’ splice site downstream of the exon and assists in U2 auxiliary 
factor recruitment on the PPT upstream of the exon. After this, the U2 snRNP can be 
incorporated through binding to the BP upstream of the exon. Additionally, SR-proteins 
are recruited to ESEs within the exon. All of these factors form a stabilizing network across 
the exon that mediate the crosstalk. Because splicing nevertheless still occurs across an 
intron, the exon definition state has to subsequently be converted into an intron recognition 
state to allow for splicing as previously described (Sharma 2008). 
 
5.5 The U1snRNP 
As already mentioned, accurate splice site recognition in early spliceosome assembly is 
crucial. One of the main players in exon definition is the U1 snRNP, recognizing the 5’ 
splice site via base-pairing of the U1 snRNA with the 5’ splice site of the pre-mRNA and 
additionally the U2 snRNA base-pairs with the BP (Figure 8). 
 
Figure 8 Exon definition during splicing initiation. Exons and introns are shown as boxes and lines. 
The colored circles indicate snRNPs with schematic representations of their respective snRNAs. 
The human U1 snRNP is relatively small, consisting of only a 165 nt long snRNA and ten 
proteins, including the seven SM proteins common to all snRNPs. The only three proteins 
specific to the U1 snRNP are U1-60K, U1-A and U1C (Patel and Bellini 2008, Pomeranz 




In general, more complex organisms have equally more complex spliceosomes. For 
example the human spliceosome includes around 80 additional mostly non-snRNP 
proteins (Fabrizio 2009, Will and Luhrmann 2011) in comparison to yeast, and 
Cyanidioschyzon merolae has an even more dramatically reduced spliceosome missing 
the U1 snRNP altogether (Stark 2015). However, when comparing the human and yeast 
U1 snRNP to each other, they seem to pose an exception. The yeast U1 snRNA alone is 
already approximately 3.5 times larger than its human counterpart (Kretzner 1987, 
Kretzner 1990). Furthermore, in the yeast system seven additional, stably associated 
proteins can be found in purified yeast U1 snRNPs, namely Luc7, Nam8, Prp39, Prp40, 
Prp42, Snu56, and Snu71. Of these, Prp42 and Snu56 have no known human homologs 
(Gottschalk 1998, Fortes 1999). 
 
Figure 9 Yeast U1 snRNP structure. The U1 snRNP is shown as cartoon in teal. The heterodimer 
important for scaffolding is highlighted in orange and pale orange. Modified from PDB entry 5UZ5 
(Li 2017). 
The first structural information on the U1 snRNP were the crystal structures of the human 
core U1 snRNP at 5.5 and 4.4 Å resolution (Pomeranz Krummel 2009, Weber 2010). From 
these structures, even though U1-A and portions of U1C and U1-70K were missing, it was 
possible to determine that the U1 snRNA forms four stem-loops (SL1 through SL4) and a 




Sm ring binds to a single-stranded uridine rich site, U1-70K binds to the SL1 with its RNA 
binding domain and U1C is able to bind the U1 core domain through interactions with the 
N-terminus of U1-70K. Contact of the U1C to the RNA could be observed at the 5’ end of 
the U1 snRNA where it base-pairs with its pre-mRNA substrate, consistent with its role as 
a stabilizer in the U1/5’ splice site base-pairing (Pomeranz Krummel 2009). X-Ray 
crystallography can be challenging for large protein RNA assemblies, as it requires highly 
stable particles that are rigid enough to enable high resolutions. With the recent 
developments in cryo-EM microscopy however, the structure determination of the 
spliceosome has progressed quickly. 
Recently, the cryo-EM structure of the yeast U1 snRNP at a resolution of 3.6 Å could be 
solved (Li 2017). This structure reveals the U1 snRNP to be overall arranged in a shape 
resembling a foot. The U1 snRNP core that forms the ball-and toes region is largely similar 
to the human core U1 snRNP, with the additionally modeled auxiliary proteins making up 
the arch and heel region (Figure 9). 
 
Figure 10 Binding of yPrp42 to the U1 snRNP core. The surface of yPrp42 is shown in orange with 
a cartoon representation of U1C and the U1 snRNA in teal and pale green, respectively. The main 
connection between the auxiliary and core U1 snRNP proteins is between the yPrp42 NTD, U1C 
and the U1 snRNA. Modified from PDB entry 5UZ5 (Li 2017). 
The auxiliary proteins yeast proteins Prp39 and Prp42 (yPrp39 and yPrp42) seem to be 
key players in the U1 snRNP. They both consist of an N-terminal half-a-tetratricopeptide 
(HAT)-repeat domain. yPrp39 and yPrp42 form a heterodimer mediated over their 




proteins to its core. The main interacting regions of core U1 snRNP proteins with the 
Prp39/Prp42 heterodimer are between the N-terminal domain (NTD) of yPrp42 and the 
yU1C C-terminal domain (CTD). In addition to this, portions of the much longer U1 snRNA 
in yeast interact with yPrp42 (Figure 10) (Li 2017). 
Recently, even more structural information on early splicing emerged. A cryo-EM structure 
of the yeast pre-spliceosome containing the U1-snRNP, the U2 snRNP and parts of a pre-
mRNA substrate could be solved by Plaschka et al. (Plaschka 2018) giving us novel 
insights into early spliceosome assembly. In this structure, the U1 snRNP and the U2 
snRNP respectively bind the 5’ splice site and BP sequence of the pre-mRNA and are 
arranged in a parallel manner to each other forming the A-complex (Figure 11). 
 
Figure 11 Structure of the yeast pre-spliceosome. U1 and U2 snRNP together with parts of the pre-
mRNA are shown in a cartoon representation. The interfacing region between yPrp39 and the U2 
snRNP is highlighted with a black circle. For color-coding see inlet. Modified from PDB entry 6G90 
(Plaschka 2018). 
Two main interfaces can be observed between the two snRNPs. The first one is a more 
transient interface that can only be found in a subset of cryo-EM images. Here a weak 




Rse1 subunit β-propellers B and C and the C-terminus of U2 Sf3a Prp9 can be seen 
(Plaschka 2018) (Figure 11). In the second interface the first two N-terminal α-helices of 
the yPrp39 stably interact with U2 3’ domain subunit of Lea1, the homolog of human U2A’ 
(Figure 11).  
Another cryo-EM structure of the yeast pre-B complex has been solved, just before the U1 
snRNA leaves the spliceosome (Bai 2018).  
 
Figure 12 Structure of the yeast pre-B spliceosome. The structure from PDB entries 5ZWN and 
5ZWM (Bai 2018) is shown in a cartoon representation. It shows the interaction between yPrp42 
and yLea1 already observed (Plaschka 2018) and reveals an additional contact between yPrp39 
and the U2 snRNA. For color-coding see inlet. 
The yPrp39/yPrp42 heterodimer seems to play an important role in positioning of the U1 
and U2 snRNPs toward each other. Here yPrp39 from the U1 snRNP contacts the U2 
specific protein yLea1 (human homolog U2A’) with its N-terminal domain. In addition to 
this, a positively charged groove on the surface of the yPrp42 NTD accommodates the U2 




It is highly interesting that the observed contacts in the stable interface between the U1 
and the U2 snRNPs in these structures are all involving protein and RNA elements that 
are either not conserved (yeast U1 snRNA SL 2-2) or have no homolog (yPrp42) in 
metazoan. Especially the yPrp39/yPrp42 heterodimer seems to play a big role in 
connecting auxiliary proteins to the U1 snRNP core (Li 2017) and mediating stable 
contacts between the U1 and U2 snRNP in the A-complex and also the pre-B complex 
(Bai 2018, Plaschka 2018). Thus, the question of how early spliceosome formation can 
function in metazoan systems lacking a Prp42 homolog arises. 
A first indication how the loss of Prp42 may be compensated in mammals came from Li et 
al.. Negative stain EM data revealed the shape of hPRPF39 to resemble the 
yPrp39/yPrp42 heterodimer and co-immunoprecipitation experiments suggest that human 
PRPF39 (hPRPF39) forms a homodimer (Li 2017). 
However, very recently a new structure of the human pre-B spliceosome has been 
published at 5.7 Å, showing a density lobe assigned as U1 snRNP (Zhan 2018) (Figure 
13). 
 
Figure 13 Structure of the human pre-B spliceosome. Cartoon representation of the components 
and the teal dotted line highlights the area the U1 snRNP is assumed to be. For color-coding see 
inlet. In the human structure the lobe of density assigned to the U1 snRNP does not contact the U2 




In this structure the U1 and U2 snRNP contact the tri-snRNP, with the U1 snRNP binding 
more flexibly. The U1 snRNP can only be located in the density map without a precise 
orientation (Zhan 2018). Interestingly here the U1 and U2 snRNPs do not contact each 
other. There is a gap of approximately 60 to 100 Å, in which density for the U4 Sm ring 
and the 3’-end sequences of the U4 snRNA can be observed (Figure 13) (Zhan 2018). 
Even in light of this new structural information, it is unclear how exactly the spatial 
positioning between the U1 and U2 snRNP occurs during A-complex formation. PRPF39 
seems to be a good target to address this question. 
 
5.6 The Spliceosomal Protein PRPF39 
Surprisingly very little is known about Prp39 in higher eukaryotes. It has been 
demonstrated to be essential in diverse human cell lines in independent CRISPR-screens 
(Blomen 2015, Hart 2015, Wang 2015). This indicates that it has a similar importance in 
metazoan compared to yeast.  
 
Figure 14 Alignment of human and murine PRPF39 protein sequence. Grey background indicates 
identical amino acid residues. The proteins are 94% conserved and most differences are in the 





Murine PRPF39 (mPRPF39) initially came to our attention because it is alternatively 
spliced in a differential manner in murine naïve versus memory T-cells. It shows high 
similarity to its human counterpart, 94 % amino acid sequence identity and 98 % similarity 
(Figure 14). We were intrigued by the fact, that a splicing factor with such an impact on 
the structural arrangement of the early-stage spliceosome is so poorly studied. 
We therefore decided to analyze mPRPF39 in depth on a structural and functional level. 
mPRPF39, like both yPrp39 and yPrp42, is predicted to be mostly made up of half a 
tetratricopeptide (HAT) repeats. HAT repeats are repetitive patterns characterized by three 
aromatic residues with a conserved spacing. Structurally they are very similar to 
tetratricopeptide repeats, arranged as two short anti-parallel α-helices connected by a loop 
(Figure 15), however they lack the highly conserved alanine and glycine residues specific 
to tetratricopeptide repeats. 
 
Figure 15 Structure of a HAT repeat. Cartoon representation of a HAT repeat in pale green with 
the three conserved amino acid residues shown as sticks in teal. 
HAT-repeat proteins are mostly involved in protein-protein and protein-RNA interactions 
and act as scaffolding proteins. Prominent members of the HAT repeat family have been 
reported to be involved in various RNA processing pathways. For example, SART3 is 
involved in splicing and translesion DNA synthesis (Huang 2018), RNA14 is important for 
cleavage during polyadenylation (Paulson and Tong 2012) and yeast Clf1 is part of the 
NineTeen complex that stabilizes the U6 snRNA in catalytic steps of splicing (Wang 2003). 
In most of these cases the HAT repeat proteins act as central interaction hubs for protein-
protein interactions and, in some cases, for RNA binding. The protein high chlorophyll 
fluorescent 107 shows sequence specific binding and remodeling of RNA in Arabidopsis 
thaliana (Hammani 2012). More relevant for this thesis, the already mentioned yPrp42 
binds the U1 snRNA SL 2-2 during splicing (Li 2017). 
Functionally, Prp39 and Prp42 are very poorly studied. The only studies pertaining to these 




yPrp39 was found to be essential for splicing (Lockhart and Rymond 1994). They could 
show that commitment complex formation only takes place in the presence of yPrp39. 
Later, in 1998, yPrp42 was characterized in more detail. Here it was found, that even 
though yPrp39 and yPrp42 show high sequence homology, they fulfill non-redundant 
functions. When yeast strains are depleted of yPrp42, splicing is arrested prior to 5’ splice 
site cleavage (McLean and Rymond 1998). Furthermore, without yPrp42, U1 snRNA 
biogenesis is compromised, resulting in incomplete U1 snRNPs unable to form stable 
complexes with pre-mRNA in vitro. This finding is consistent with yPrp42 scaffolding 





5.7 Aim of This Study 
The spliceosome is difficult to analyze as a whole because of its high complexity and 
dynamic nature. This thesis deals with steps in early spliceosome formation.  
At the start of this thesis, very little was known about PRPF39. In particular, very little 
experimental structural information was available on this protein. The only relevant papers 
on Prp39 were early studies in the yeast system (Lockhart and Rymond 1994, McLean 
and Rymond 1998). In the course of my thesis more studies on the early spliceosome have 
been performed, shedding light on the structural and functional relevance of Prp39 in the 
yeast system. However, the fundamental question of how splicing could function in a 
system without a Prp42 homolog remains unclear.  
Thus, the overall aim of this work was 1) to gather information, by means of structural and 
biochemical analyses that will allow us to better understand the role of eukaryotic PRPF39 
in early splicing and 2) to determine if Prp39 takes over the function of the lacking Prp42 
homolog in higher eukaryotes. To this end, the following specific goals were proposed: 
1. Establishment of efficient recombinant production pipeline for murine PRPF39, 
using different fragments of this protein to increase chances of expression success. 
2. Establishment of efficient purification protocols for mPRPF39 to obtain sufficient 
amounts of highly homogeneous material for further structural and functional 
studies. 
3. Crystallization, structure determination and crystal structure analysis of mPRPF39. 
4. Establishment of production of efficiently splicing nuclear extracts from eukaryotic 
cells for use in functional studies. 
5. Structure-based functional analyses, such as targeted mutagenesis followed by in 
vitro splicing assays. 
6. Comparison of the yeast system with the metazoan system on a structural and 
phylogenetic level. 
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6 Materials and Methods 
6.1 Material 
6.1.1 Instruments and Consumables 
Instrument       Company 
Acupuncture needle      Moxom Medical, Germany 
Agarose gel chambers + combs    Peqlab, Germany 
Äkta purification systems     GE Healthcare, Germany 
Beakers       Schott, Germany 
Beamline 14.2      HZB, Berlin, Germany 
Beamline 14.3      HZB, Berlin, Germany 
Beamline P14, Petra III     DESY, Hamburg, Germany 
Cell culture tubes      Greiner Bio-One, Germany 
Centrifuge Allegra X-15R     Beckman Coulter, Germany 
Centrifuge Avanti J-26 XP     Beckman Coulter, Germany 
Centrifuge 5417R      Eppendorf, Germany 
Centrifuge 5810R     Eppendorf, Germany 
Clean bench       Laminair 1.8 Holton, Danmark 
Concentrators      Millipore, USA 
Conical flasks      Schott, Germany 
Cryo loops       Hampton Research, USA 
Crystallisation plates      MRC Molecular Dimensions, UK 
Crystallisation robot      Zinsser, Germany 
Cylinders       Isolab, Germany 
Disposable pipettes      Sarstedt, Germany 
Dialysis membranes      Spectra/Por, USA 
Electroporation cuvettes     Peqlab, Germany 
Electroporator EasyjecT Prima    Equibio, UK 
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Electrophoresis power supplies    BioRad, Germany 
Falcon tubes       Greiner Bio-One, Germany 
Glass flasks       Schott, Germany 
Glass pipettes      Hirschmann, Germany 
Heating block HLC      DITABIS, Germany 
HT multitron culture shaker     Infors, Switzerland 
Ice machine       Ziegra, UK 
Incubator       Heraeus, Germany 
Inoculation loop      Sarstedt, Germany 
Magnetic stirrers      IKA, Germany 
Micro scale XS205 Dual Range    Mettler Toledo, Germany 
Microscope       Olympus, Germany 
Milli-Q synthesis A10     Millipore, USA 
Multitron culture shaker     Infors HT, Switzerland 
Nanodrop 2000 spectrophotometer    Peqlab, Germany 
Needles       Henke Sass Wolf, Germany  
Rocking platform      Biometra, Germany 
Parafilm       Pechiney Plastic Packaging, USA 
pH meter Professional Meter PP-20   Satorius, Germany 
Phosphoimager Typhoon FLA 7000   GE Healthcare, Germany 
Pipettes       Abimed, Germany 
Pipette tips       Sarstedt + Greiner Bio-One, Germany 
Polyvinylidene difluoride membrane   Merck, Germany 
Power supplies     Bio-Rad, German 
Scale XS4002S Delta Range    Mettler Toledo, Germany 
Scanner for gel documentation    Epson, Germany 
SDS-PAGE chambers, combs, glass plates  BioRad, Germany 
Sonificator Sonoplus      Bandelin, Germany 
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Speed vac concentrator 5301    Eppendorf, Germany 
Sterile Filters 0.22 µm    Sarstedt, Germany 
Surgical blades      Martin, Germany 
Syringes       Braun, Germany  
Table centrifuge 5415R     Eppendorf, Germany 
Thermo cycler Star 2X Gradient    Peqlab, Germany 
Thermo mixer compact     Eppendorf, Germany 
Tubes        Sarstedt, Germany 
Tunair flasks       Sigma-Aldrich, Germany 
Vortex Genie 2      Scientific Industries, USA 
Weighting dishes      Roth, Germany 
 
6.1.2 Chemicals 
Chemical       Company 
2-(N-morpholino)ethanesulfonic acid (MES)  Roth, Germany 
2-Propanol      Roth,Germany 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic Roth, Germany 
acid (HEPES) 
ABsolute QPCR SYBR Green Mix    Thermo Fisher 
Acetic acid       Roth, Germany 
Acrylamide : bis-acrylamide 37.5 : 1   Roth, Germany 
Agarose       Bio&Sell, Germany 
Ammonium chloride      Roth, Germany 
Ammonium persulfate (APS)    Merck, Germany 
Ampicillin (Amp)     Roth, Germany 
Amylose resin      New England Biolabs, USA 
Boric acid       Roth, Germany 
Bovine serum albumin (BSA)   Roth, Germany 
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Bromophenol blue      Roth, Germany 
Calcium chloride dihydrate     AppliChem, USA 
Chloramphenicol (Cm)     Roche, Germany 
Cobalt (II) chloride hexahydrate    Sigma-Aldrich, Germany 
Coomassie Brilliant Blue G250    Serva, Germany 
Coomassie Brilliant Blue R250    Serva, Germany 
Copper (II) chloride dihydrate    Roth, Germany 
Cycloheximide (CHX)     Roth, Germany 
D(+)-glucose       Roth, Germany 
Desoxyribnucleotides (dNTPs)    Sigma-Aldrich, Germany 
Disodium hydrogen phosphate    Roth, Germany 
Dithiothreitol (DTT)      Sigma-Aldrich, Germany 
DMEM High Glucose     Biowest, Germany 
DNaseI (2mg/ml)      Sigma-Aldrich, Germany 
Ethanol       Roth, Germany 
Ethidium bromide      Roth, Germany 
Ethylene-diamine-tetra-acetic acid (EDTA)   Roth, Germany 
Fetal bovine serum (FBS)    Biochrome, Germany 
Glycerole       Roth, Germany 
Glycine       Roth, Germany 
Hydrochloric acid      Merck, Germany 
Imidazole       Roth, Germany 
Iron (III) chloride hexahydrate    Sigma-Aldrich, Germany 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Roth, Germany 
Kanamycine (Kan)     Roth, Germany 
Lactose monohydrate     Roth, Germany 
Lysozyme (10mg/ml)      Sigma-Aldrich, Germany 
Magnesium acetate tetrahydrate    Fluka, Germany 
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Magnesium chloride hexahydrate    Merck, Germany 
Magnesium sulfate heptahydrate    Roth, Germany 
Maltose       Merck, Germany 
N,N,N’,N’-Tetraethylenediamide (TEMED)   Roth, Germany 
Nickel (II) chloride hexahydrate    Merck, Germany 
Penicillin/Streptomycin     Biowest, Germany 
Peptone       Roth, Germany 
Polyethylene glycol monomethyl ether 5000 Fluka, Germany 
Potassium dihydrogen phosphate    Roth, Germany 
RNA Tri-Flüssig     Bio&Sell, Germany 
RPMI-medium-1640     Biowest, Germany 
Sodium chloride      Roth, Germany 
Sodium dodecylsulfate     Roth, Germany 
Sodium molybdate dihydrate    Merck, Germany 
Sodium selenite pentahydrate    Roth, Germany 
Sodium sulfate      Roth, Germany 
Tris-(hydroxylmethyl)-aminomethane (TRIS)  Roth, Germany 
Tween-20       Roth, Germany 
Xylene cyanol      Sigma-Aldrich, Germany 
Yeast extract       AppliChem, USA 
Zinc sulfate heptahydrate     Roth, Germany 
β-Mercaptoethanol     Roth, Germany 
 
6.1.3 Buffers, Media and Stock Solutions 
Solution      Composition 
5052 (50x)      25 % Glycerol (v/v) 
      10 % Lactose monohydrate (w/v) 
      2.5 % Glucose (w/v) 
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Amp       100 mg/ml 
 
Auto-induction media (1L)   95.8 % ZY medium (v/v) 
      2 % 5052 (50x) (v/v) 
      2 % M (50x) (v/v) 
      0.2 % Magnesium sulfate (1M) (v/v) 
      0.02 % metals (1000x) (v/v) 
 
Buffer D     20 mM HEPES, pH 8.5 
      100 mM KCl 
      0.2 mM EDTA 
      20 % Glycerol 
      1 mM DTT 
      0.5 mM phenylmethylsulfonyl fluoride 
 
Cm      34 mg/ml 
 
Coomassie staining solution    42.5 % Ethanol (v/v) 
      10 % Acetic acid (v/v) 
      0.6 % Coomassie Brilliant Blue R250 (w/v) 
      0.15 % Coomassie Brilliant Blue G250 (w/v) 
 
Coomassie destaining solution I   40 % Ethanol (v/v) 
      20 % Acetic acid (v/v) 
 
Coomassie destaining solution II   10 % Acetic acid (v/v) 
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DNA loading dye (5x)    30 % Glycerole (v/v) 
      0.5 x TRIS-borate-EDTA (TBE) buffer (v/v) 
      0.033 % bromophenol blue (w/v) 
      0.033 % xylene cyanol (w/v) 
 
FD Buffer green (10x)    not listed 
Fixing solution    10 % methanol (v/v) 
      10 % acetic acid (v/v) 
 
Gentamicin      7 mg/ml 
 
reduced glutathion (GSH) elution buffer 50 mM Tris/HCl, pH 8.4 
      2 mM DTT 
      10 mM GSH 
 
High salt-tris-buffered saline with   50 mM Tris/HCl, pH 7.5 
Tween20 (TBST)    400 mM NaCl 
      0.1% Tween-20 
 
Kan       50 mg/ml 
 
Lysogeny broth (LB) medium   1 % Peptone (w/v) 
      0.5 % Yeast extract (w/v) 
      0.5 % Sodium chloride (w/v) 
 
Low salt-TBST    50 mM Tris/HCl, pH 7.5 
      150 mM NaCl 
      0.1 % Tween-20 
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Lysis Buffer (protein expression)  50 mM Tris/HCl, pH 8.5 
      2 mM DTT 
 
Lysis Buffer (cell culture)   60 mM Tris/HCl, pH 7.5 
      30 mM NaCl 
      1 mM EDTA 
      10 % Glycerol 
      1 % Triton X-100 
 
M (50x)      2.5 M Ammonium chloride 
      1.25 M Disodium hydrogen phosphate 
      1.25 M Monopotassium phosphate 
      250 mM Sodium sulfate 
 
Metals (1000x)     50 mM Iron chloride 
      40 mM Calcium chloride 
      10 mM Manganese (II) chloride tetrahydrate 
      10 mM Zinc sulfate heptahydrate 
      4 mM Copper (II) chloride dihydrate 
      4 mM Sodium molybdate dihydrate 
      4 mM Sodium selenite pentahydrate 
      4 mM Boric acid 
      2 mM Cobalt (II) chloride hexahydrate 
      2 mM Nickel (II) chloride hexahydrate 
 
Radioimmunoprecipitation assay  10 mM Tris/HCl, pH 7.5 
(RIPA) buffer     100 mM NaCl 
      2 mM EDTA 
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      1% NP-40 
      with proteinase inhibitors 
 
Reverse Transcriptase-Buffer  12.50 mM DTT 
      12.50 mM Tris/HCl, pH 8.0 
      7.50 mM MgCl2 
      1.25 µM dNTP 
 
Taq-Polymerase-Buffer   0.5 M KCl 
      0.1 M Tris/HCl, pH 8.3 
      15 mM MgCl2 
      0.01 % Gelatine 
 
Tetracycline      15 mg/ml,  
 
SEC Buffer     20 mM Tris/HCl, pH 8.5 
      200 mM NaCl 
      2 mM DTT 
 
SDS loading dye (6x)    60 mM Tris/HCl, pH 6.8 
      1 mM EDTA-NaOH 
      16 % Glycerole (v/v) 
      2 % SDS (w/v) 
      0.1 % Bromophenol blue (w/v) 
 
SDS-PAGE running buffer (10x)   1920 mM Glycine 
      250 mM Tris/HCl 
      1% SDS (w/v) 
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Separation gel buffer    1.5 M Tris/HCl, pH 8.8 
      0.4 % SDS (w/v) 
 
Stacking gel buffer     500 mM Tris/HCl, pH 6.8 
      0.4 % SDS (w/v) 
 
T4 DNA ligase buffer (10x)    50 mM Tris/HCl, pH 7.5 
      10 mM Magnesium chloride 
      10 mM DTT 
      1 mM ATP 
 
TRIS-Acetat-EDTA (TAE) buffer   40 mM Tris/HCl, pH 8.0 
      20 mM Acetic acid 
      2 mM EDTA 
 
TBE buffer      100 mM Boric acid, pH 8.0 
      100 mM Tris/HCl 
      2.5 mM EDTA 
 
Transfer Buffer:    5.82 g/l Tris-Base 
      2.93 g/l Glycin 
      3.75 ml SDS (10% Stock) 
      20 % Methanol 
 
Phusion-Buffer:    Thermo Scientific F-518 5x Phusion HF 
 
Urea-PAGE loading buffer   210.5 µg/ml Bromphenolblau 
      210.5 µg/ml Xylencyanol 
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      26.3 mM EDTA 
      in Formamide 
 
Urea-PAGE running buffer   0.5 x TBE 
 
ZY medium      1 % Peptone (w/v) 
      0.4 % Yeast extract (w/v) 
 
6.1.4 Kits 
Kit       Company 
Nucleo Spin Gel and PCR Clean-up  Macherey-Nagel, Germany 
DNA, RNA, and Protein Purification  Macherey-Nagel, Germany 
NucleoBond Xtra Midi   Macherey-Nagel, Germany 
 
6.1.5 Enzymes 
Name        Company 
Endoproteinase ArgC from mouse submarillary glands  Roche, Germany 
(0.5 µg/µl) 
Carboxypeptidase Y (0.1 µg/µl)    Sigma-Aldrich, Germany 
Chymotrypsin (0.5 µg/µl)     Roche, Germany 
DNase I       Roche, Germany 
Endoproteinase Glu-C from Staphylocossusaereus V8  Sigma-Aldrich, Germany 
(0.5 µg/µl) 
Elastase (0.13 µg/µl)      Sigma-Aldrich, Germany 
Endoproteinase LysC from Lysobacter enzymogenes  Sigma-Aldrich, Germany 
(0.5 µg/µl) 
PreScission protease      Home-made, recombinant 
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Proteinase K       Sigma-Aldrich, Germany 
Restriction endonucleases  New England Biolabs, 
Germany 
Reverse transcriptase (RT) New England Biolabs, 
Germany 
RNase A, T1  Ambion, Germany 
RNasin       Molox, Germany 
Subtilisin (0.1 µg/µl)      Sigma-Aldrich, Germany 
T4 DNA ligase New England Biolabs, 
Germany 
T4 polynucleotide kinase New England Biolabs, 
Germany 
Thermolysin       Sigma-Aldrich, Germany 




Strain  Descritption     Use 
BL21  deficient in lon and ompT  general purpose expression host for  
  proteases    plasmids 
BL21 pLysS deficient in lon and ompT  high-stringency expression host 
  proteases 
BL21 pRare deficient in lon and ompT  expression host; allows expression of 
  proteases, contains plasmid  genes encoding tRNAs for rare  
  encoding argU, ileY, and  argenine codons AGA and AGG,  
  leuW     isoleucine codon AUA, and leucine  
       codon CUA 
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6.1.7 Vectors  
Name  Description      Reference 
pGEX6P1  Vector for expression of genes with a  GE Healthcare 
  PreScission protease-cleavable N-terminal 
  GST-tag in E. coli; AmpR  
pEGFP-N3 Vector for expression of genes with a  Clontech 
  C-terminal GFP-tag in eukaryotic cell 
pFlag-N3 Vector for expression of genes with a  self made 
  C-terminal Flag-tag in eukaryotic cells 
 
6.1.8 Cloned Constructs 
Vector      Insert 
pGEX6P1     PRPF39 full-length 
pGEX6P1     PRPF39ΔN 
pGEX6P1     PRPF39ΔC 
pGEX6P1     PRPF39ΔNΔC 
pGEX6P1     PRPF39R458D 
pGEX6P1     PRPF39R464D 
pGEX6P1     PRPF39Y536W 
pGEX6P1     PRPF39E576K/D577K 
pGEX6P1     PRPF39R458D, R464D 
pGEX6P1     PRPF39R458D, Y536W 
pGEX6P1     PRPF39R464D, Y536W 
pGEX6P1     PRPF39R458D, R464D, Y536W 
pGEX6P1     PRPF39E576K/D577K, Y536W 
pEGFP-N3     PRPF39 full-length 
pEGFP-N3     PRPF39R464D 
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pEGFP-N3     PRPF39E576K/D577K 
pFlag-N3     PRPF39 full-length 
pFlag-N3     PRPF39R464D 
pFlag-N3     PRPF39E576K/D577K 
 
6.1.9 Primers 
The nucleotide residues shown in red signify changes in the sequence for mutagenesis. 
Primer       Sequence 
mPRPF39 fwd for pGEX6P1    GCGGATCCATGCAAAACTCCCACATGGAAGAGT  
mPRPF39 rev for pGEX6P1    GCGTCGACTCAAGTTGGAGGTGGAGGATAATACTG 
mPRPF39 fwd for GFP/Flag    GCCTCGAGATGCAAAACTCCCACATGGAAGAGT 
mPRPF39 rev for GFP/Flag    GCGGATCCAGTTGGAGGTGGAGGATAATACTGTCC 
39_R458D_fwd     CAATGGTTCGATTGGACAGAGTAAGTTTAG 
39_R458D_rev     CTAAACTTACTCTGTCCAATCGAACCATTG 
39_R464D_fwd     GTAAGTTTAGAAGACCGGCATGGAAATATG 
39_R464D_rev     CATATTTCCATGCCGGTCTTCTAAACTTAC 
39_Y536W_fwd     CTTGAAATGGAATGGAGTTGTGACCTCAAGC 
39_ Y536W_rev     GCTTGAGGTCACAACTCCATTCCATTTCAAG 
39_ED476/7KK_fwd     GAAAAGTGGAATTCCTTAAAAAGTTTGGTTCAGATG 
39_ ED476/7KK _rev     CATCTGAACCAAACTTTTTAAGGAATTCCACTTTTC 
PRPF39 fwd splice PCR    ACCATTGGAAAAGGCTCAGC 
PRPF39 rev splice PCR    TCTGCTGAAGACATGCCTCA 
 
6.1.10 Crystallization Screens 
Screen    Supplier 
Classic    Qiagen, Germany 
Core I to IV    Qiagen, Germany 
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Index     Hampton Research, USA 
SaltX     Hampton Research, USA 
Additive Screen   Hampton Research, USA 
 
Protein   Screen  Concentration 
mPRPF39full-length  Classic  7 mg/ml 
mPRPF39full-length   Index   7 mg/ml 
mPRPF39full-length   SaltX   7 mg/ml  
mPRPF39full-length   Additive Screen 7 mg/ml  
mPRPF39ΔC   Classic  3.5; 7; 14; 20.4 mg/ml 
mPRPF39ΔC   Core I to IV  7; 14 mg/ml 
mPRPF39ΔC   Index   3.5; 20.4 mg/ml 
 
6.1.11 Software and Websites 
Software     Reference 
ApE      M. Wayne Davis, USA 
Coot       (Emsley and Cowtan 2004) 
CorelDRAW     Corel Corporation, USA  
ExPASy - ProtParam tool    http://web.expasy.org/protparam/  
ImageQuantTL    GE Healthcare, Germany 
iMOSFLM 1.0.7.     (Battye 2011) 
Phaser      (McCoy 2007) 
PHENIX suite     (Adams 2002) 
PyMOL     Schrödinger LLC, USA  
PHYRE2 Protein Fold Recognition Server (Kelley 2015) 
XDS       (Kabsch 2010) 
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6.1.12 Information on Organisms Analyzed in This Study 





















































gossypii 4619435 4618919 NR_149369.1 
 







Gallus gallus 100858094 
 
CM000094.4 122405288-122405125 
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africana 13882673 13883163 HE650821.1 1584550-1585071 
Kazachstania 
naganishii 34526819 34523735 HE978319.1 165173-164349 
Kluyveromyces 
lactis 2896694 2892680 CR382124.1 1640297-1640824 
Kluyveromyces 
marxianus 34714086 34715797 AP012217.1 1292327-1292890 
Lachancea 
































Ovis aries 101105691 
 
CM001607.2 36635321-36635483 





Materials and Methods 
 
37 






Papio anubis 101018467 
 
CM001504.2 15159947-15159784 























blattae 14494650 14492777 HE806322.1 39259-38548 
Tetrapisispora 
phaffii 11530654 11531712 HE612870.1 376574-377321 
Torulaspora 
delbrueckii 11501180 11504149 HE616742.1 108192-107653 




yces rouxii 8206003 8201844 CU928178.1 1248575-1249130 
 
6.2 Methods 
6.2.1 Nucleic Acid Methods  
6.2.1.1 Determination of Nucleic Acid Concentration  
To determine the concentration of nucleic acids, the light absorption of an aqueous 
solution was measured at the wavelength of 260 nm using a Nanodrop spectrophotometer. 
The concentration was then calculated using theoretical absorption values at 260 nm (as 
described in Sambrook, 1989).  
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double-stranded DNA  1 OD260 = 50 μg/ml  
single-stranded DNA   1 OD260 = 33 μg/ml  
single-stranded RNA   1 OD260 = 40 μg/ml  
 
6.2.1.2 Agarose Gel Electrophoresis for DNA 
Agarose gel electrophoresis was used both for analytical visualization and purification of 
preparative amounts of DNA. Agarose gels were prepared with agarose concentrations 
between 1-2 % in 1 x TAE and ethidium bromide in a concentration of 0.05 mg/L, 
depending on the DNA fragment size. Before loading the samples were mixed with DNA 
loading dye and a commercial DNA ladder was applied to every gel. The gels were run at 
a constant voltage of 135 V in 1 x TAE buffer. DNA bands were visualized by UV 
illumination at 254 nm. DNA bands were cut from the gel with a razor blade and the DNA 
was extracted from the gel using a kit following the instructions of the manufacturer. 
 
6.2.1.3 Polymerase Chain Reaction (PCR) 
PCR was used for amplification of genes or gene fragments. Phusion polymerase was 
used according to the instructions of the manufacturers. Typical PCR conditions are shown 
below (Table 2). 
Table 2 Conditions for PCR 
Compound Amount 
DNA Template (plasmid DNA 1µg/ml) 0.5 µl 
Forward primer (100ng/ul) 0.5 µl 
Reverse primer (100ng/ul) 0.5 µl 
5 x PHU Buffer 5.0 µl 
dNTPs (20mM) 0.5 µl 
PHU DNA polymerase 0.5 µl 
H2O 17.5 µl 
Total volume 25 µl 
 





(°C) Time Cycles 
Initial denaturation 98 30 s 1 
Denaturation 98 10 s 
 
Annealing 56-60 20 s 30 
Extension 72 30-150 s 
 
Final Extension 72 7 min 1 
 
6.2.1.4 Site-directed Mutagenesis 
Desired mutations were introduced according to the QuikChange II XL Site-Directed 
Mutagenesis Kit manufacturer's instructions. The resulting clones were verified by DNA 
sequencing. 
 
6.2.1.5 Restriction Digestion and Ligation of DNA 
Restriction digestions were carried out to generate compatible ends in vectors and PCR 
products for subsequent ligation reactions. Buffers and temperatures were chosen 
according to the manufacturer's instruction. The conditions for the restriction digestion are 
listed below (Table 3). 
 
Table 3 Conditions for restriction digestion 
Compound Amount 
Insert/Vector 20.5 µl / 1 µl + 19.5 µl H2O 
Enzyme 1 1 µl 
Enzyme 2 1 µl 
10 x Buffer 2.5 µl 
 
To decrease the vector background 2.9 µl antarctic phosphatase buffer and 1.1 µl antarctic 
phosphatase were added to the vectors for 5 minutes. Since phosphatase-treated 
fragments lack the 5´ phosphoryl termini required by ligases, they cannot self-ligate. 
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For ligation, the digested DNA was resolved on a preparative agarose gel and the band 
containing the desired product was excised and extracted as explained in Agarose Gel 
Electrophoresis for DNA. Ligation reactions typically contained 7 µl digested insert and 1 
µl digested vector. Reaction mixtures were incubated at room temperature for 1 h. 
 
6.2.1.6 Plasmid Isolation from Escherichia coli (E. coli) Cells 
A single colony from an overnight grown LB-agar plate was used to inoculate LB medium. 
Cells were grown in 3 ml or 100 ml LB medium overnight at 37 °C. Plasmid purification 
was carried out using Mini- or Midiprep kits, according to the manufacturer's instructions. 
 
6.2.1.7 Plasmid Verification 
All cloned plasmids were verified for the presence of the correct insert by analytical 
restriction digestion. Sequences of the inserts which showed the correct size in agarose 
gel analysis were verified by DNA sequencing. 
 
6.2.1.8 Isolation of RNAs 
Cells for RNA extraction were harvested (7000 rpm, 1 min) and the cell precipitate was 
solved in 500 μl “RNA-Tri-flüssig”. Next 100 μl chloroform was added and the samples 
were vortexed and incubated on ice for 10 min. Phase separation was achieved by 
spinning the tubes for 15 min at 4 °C at full speed. The aqueous phase was transferred to 
a new tube containing 300 μl ice-cold isopropanol. The tubes were again vortexed and 
centrifuged for 15 min at 4 °C at full speed to pellet the precipitating RNA. The RNA 
precipitate was washed three times with 70 % ethanol and then dissolved in 12 μl Milli-Q-
water. The concentration and the purity of the RNA were determined with the 
Nanophotometer P330 from Implen. 
 
6.2.1.9 In Vitro Transcription of RNAs for In Vitro splicing 
A linearized plasmid which includes a T7 promoter as well as the sequence of the pre-
mRNA template was used as starting material. After incubation at 37 °C for 2 h in the 
presence of T7 polymerase, DNase was added for 15 min to degrade the template. The 
generated RNA transcript was precipitated with PCI and ethanol and resuspended in 40 
μl water. The efficiency of the reaction was checked by loading 2 μl on a 10 % denaturing 
PAGE. 
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6.2.1.10 RT-PCR and RT-qPCR 
RT-PCRs were done as previously described (Preussner 2014). Briefly, RNA was 
extracted using RNA Tri-Flüssig and 1 mg RNA was used in a gene-specific RT-reaction. 
Low-cycle PCR with a 32P-labeled forward primer was performed, products were separated 
by denaturing PAGE and quantified using a phosphoimager and ImageQuantTL software. 
For qRT-PCR up to 4 gene-specific primers were combined in one RT reaction. The qPCR 
was then performed in a 96-well format using the ABsolute QPCR SYBR Green Mix on a 
Stratagene Mx3000P instrument. qPCRs were performed in duplicates, mean values were 
used to normalize expression to mRNA of GAPDH. Quantifications are given as mean 
values, error bars represent standard deviation, p values were calculated using Student’s 
unpaired t test. Significance is indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001).  
 
6.2.1.11 T-cells and RNA Sequencing 
T-cells generation and RNA sequencing were performed by Thomas Schüler, Otto-von 
Guericke University Magdeburg and Bernd Timmermann Max-Planck-Institute for 
Molecular Genetics Berlin, respectively. Naïve and memory CD8+ T cells were generated 
using the OT-I system as described previously (Stoycheva 2015, Deiser 2016). RNA-Seq 
was done essentially as described (Herdt 2017). Briefly, total RNAs were prepared using 
RNA-Tri and further purified using the RNeasy mini kit in combination with a DNase I 
treatment. RNA sequencing libraries were prepared by using the TruSeq mRNA Library 
Preparation kit. 125-bp paired-end reads were generated by using a HiSeq 2500 
sequencer (Illumina) with V4 sequencing chemistry. Triplicate samples from naïve and 
memory T cells were sequenced (around 40x106 reads per sample) and analyzed using a 
MISO-based pipeline (Preussner 2017).  
 
6.2.2 Cell and Cell Culture Methods 
6.2.2.1 E. coli Strains and Cultivation 
E. coli cells were grown in liquid medium or on agar plates supplemented with adequate 
antibiotics in the following concentrations: 
- Amp 100 μg/ml, 
- Cm 34 μg/ml, 
- Kan 50 μg/ml. 
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6.2.2.2 Transformation and Selection of E. coli Cells 
For electroporation, 50-100 ng DNA were mixed with 50 μl electro-competent E. coli cells 
on ice. The mixture was transferred to an ice-cold electroporation cuvette (1-2 mm 
electrode gap) and subjected to a 4.8 ms pulse of 2.5 kV. Cells were collected in 1 ml of 
LB medium and incubated for 1 h at 37°C in a shaker. Subsequently the cells were 
centrifuged and resuspended in 250 μl LB medium and streaked out on an agar-plate 
containing the selective antibiotics.  
For chemical transformation, 100-200 ng of plasmid DNA was mixed with 100 μl of 
chemically competent E. coli cells and incubated for 10 min on ice. Ice-cold cells were then 
heat-shocked for 1 min at 42°C and cooled on ice for 5 min. Cells were mixed with 200 μl 
of LB medium and incubated at 37°C for 1 h in a shaker. The cells were collected and 
selected on LB-agar plates supplemented with appropriate antibiotics. 
 
6.2.2.3 Protein Expression in E. coli 
Protein expression was conducted using chemically competent E. coli cells. The cells were 
inoculated with 20 ml preculture and grown in LB medium with the appropriate antibiotics 
at 37°C until an optical density (OD) of 0.6 to 1 was reached. At this point the cultures and 
the shaker were cooled to 18°C and induced with 1 mM IPTG. Expression was performed 
overnight. 
For auto-induction cells were grown in ZYM-5052 (50 mM phosphate) auto-inducing 
complex medium (Studier 2005). Complex media containing enzymatic digests of 
casein and yeast extract are extensively used since they support growth of a wide 
range of E. coli strains, with different nutritional requirements, and cultures typically 
grow several times faster than in simple mineral salts media supplemented with 
glucose as the only carbon source. However, due to small amounts of lactose, inducing 
activity is fairly common in complex media. 
Auto-induction depends on mechanisms bacteria use to regulate the use of carbon 
sources present in the growth medium. Lactose is prevented from inducing production 
of target protein by compounds that can be depleted during growth, such as glucose, 
glycerol and amino acids. Consequently, if glucose is present in the medium, it 
prevents the uptake of lactose. Ideally, the expression strain would grow to saturation 
in auto-inducing media, when depletion of inhibitory factors would allow cells to take 
up lactose and convert it to allolactose, the natural inducer of the lac operon. Induction 
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unblocks both the lacUV5 and T7lac promoters of T7 RNA polymerase and target 
protein, respectively, and leads to large scale expression levels in highly saturated 
cultures. 
 
6.2.2.4 Eukaryotic Cell Lines and Their Cultivation 
The cell lines used in this study are listed in Table 4:  
Table 4 Cell lines used in this study 
Name of the cell line  Cell type  Growing system  
Jukat (Jsl1)  Human T lymphocytes  Suspension culture  
El4  Mouse T lymphocytes  Suspension culture  
HEK293T  Human embryonic kidney 
cells  
Adherent culture  
Suspension cells were cultivated in RPMI-medium-1640 (1x) + GlutaMAX TMI (+/+) 
containing 10 % heat-inactivated FBS and Penicillin/Streptomycin 1:100. 
Adherent cells were cultivated in DMEM High Glucose containing heat-inactivated 10 % 
FBS and Penicillin/Streptomycin 1:100. Cell seeding was done in DMEM High Glucose 
containing only 10 % FBS but no antibiotics. 
Both suspension and adherent cells were grown at 37 °C with 5 % CO2 in a Heraeus 
incubator from Thermo Scientific. 
 
6.2.2.5 Plasmid and siRNA Transfection 
For plasmid transfection HEK293T cells were seeded into 6 well plates in a concentration 
of 3.5 * 105/well in 1.5 ml medium. The next day the cells were transfected with the desired 
plasmids. To this end a total of 2 µg plasmids were incubated in 250 µl OptiMEM. Then 5 
µl RotiFect in a total volume of 250 µl OptiMEM were added to the samples. After 20 
minutes of incubation the samples were dripped into the wells. 
For siRNA transfection 0.5×105 HEK293T cell were seeded in a 12-well plate and 
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6.2.2.6 Harvesting Proteins 
2 days post transfection the HEK293T cells were harvested. First the medium was 
removed, then the cells were washed with 1.5 ml PBS per well. Subsequently 250 μl Flag 
Lysis Buffer was added to every well, the cells were transferred to eppis and chilled at 4 
°C for 10 minutes while occasionally vortexing them. The supernatant is collected after 15 
minutes centrifugation at 13,000 rpm 
 
6.2.2.7 Immuno Precipitation (IP) 
IPs were performed as previously described with minor adjustments (Heyd and Lynch 
2010). For IPs HEK293T cells were lysed in RIPA buffer, 100 ug of lysate were incubated 
in 500 µl RIPA buffer containing 400 mM NaCl (if not otherwise mentioned) and 3% BSA. 
After 1h rotation at 4°C, prewashed anti-FlagM2 beads were added and 4°C rotation was 
continued overnight. Beads were washed 5 times in RIPA buffer and after the last wash 
SDS-sample buffer was added, samples were boiled and analyzed by SDS-PAGE and 
Western blot. 
The following antibodies were used for Western blotting: Flag (2368, Cell Signaling), GFP 
(B-2, Santa Cruz). 
 
6.2.3 Protein Methods 
6.2.3.1 Determination of Protein Concentration 
The protein concentration can be determined by measuring the UV-absorption at 280 nm. 
The molecular weight and the extinction coefficient were calculated with ProtParam tool 
(www.expasy.org) and the protein concentrations were automatically calculated according 
to the Lambert-Beer law: 
𝐴 =  𝜀 ∗ 𝑐 ∗ 𝑑 
A: absorption at 280nm 
ε: molar absorptivity 
c: concentration [mg/ml] 
d: path length 
As reference-solution the appropriate buffer was chosen. 
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6.2.3.2 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is a method of separating proteins by size in a gel in an electrical field. Proteins 
bind the detergent sodium dodecyl sulfate (SDS) to form negatively charged SDS-protein-
complexes with a constant charge per unit mass ratio. Especially in combination with DTT 
SDS denatures proteins and inhibits protein-protein interactions. Thus, the proteins differ 
only in size and have comparable hydrodynamic properties. During the electrophoresis the 
SDS-protein complexes migrate to the positive pole. The molecular sieve effect of the 
porous polyacrylamide matrix separates the SDS-protein complexes according to their 
Stokes radius which in this case means according to their molecular weight. 
The samples were diluted if necessary. SDS-6x sample-buffer was added to the samples 
and then they were heated to 95°C for approximately 5 minutes. 20 μl of every sample 
was loaded onto a gel. As reference a Protein Ladder was loaded on every SDS-PAGE. 
Gels were run at 250 V for about 45 minutes. For Western Blot the gels were run at 136 V 
for approximately 90 minutes.  
Coomassie staining solution is applied to the finished gel and excess coloring agent is 
removed by the Coomassie destaining solution so that only the bands with proteins are 
colored blue. This method is sensitive in a range of 200 ng to 400 ng protein. The distance 
travelled by each band is compared with the marker to determine the size of the proteins 
(Fairbanks 1971). 
The SDS-PAGE gels were prepared according to Table 5. 
 
Table 5 SDS-PAGE gel composition 
 
Stacking 
gel Running gel 
Gel concentration  4% 12.5% 17.5% 
Stacking gel buffer  2.5 ml - - 
Running gel buffer - 5.0 ml 5.0 ml 
ddH2O 6.2 ml 6.6 ml 3.4 ml 
30% Bis-acrylamide  1.3 ml 8.4 ml 11.6 ml 
10% APS 100 μl 100 μl 100 μl 
TEMED 10 μl 10 μl 10 μl 
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6.2.3.3 Western Blot 
Western Blot is an analytical method to detect specific proteins after an SDS-PAGE. First 
the proteins are transferred electrophoretically from the SDS-PAGE gel to the methanol 
activated blot polyvinylidene difluoride membrane using a semidry-blot-system at 75 mA 
per gel for 1.5 hours. First three Whatman papers drenched in blot buffer are applied to 
the electrode bubble free. Then the activated membrane is laid on to the papers. The SDS-
PAGE gel is placed on top and an additional layer of three drenched Whatman papers is 
added onto the stack as bubble free as possible. 
After the blot-transfer the free binding sites on the membrane are blocked for one hour at 
room temperature in 2% BSA in LS-TBST. Then the membrane is incubated with the 
appropriate primary antibodies diluted in 2% BSA in LS-TBST over night at 4°C and 
washed 3 times 5 minutes in HS-TBST. After that the membrane was incubated for one 
hour at room temperature in α-IgG horseradishperoxidase-coupled antibodies from anti-
rabbit or mouse in 2% BSA in LS-TBST (1:20,000) it was washed once for 15 minutes and 
2 times for 5 minutes. Following this, developing solution was applied to the membrane 
and a film was exposed. The film was developed in an Amersham pharmacia biotech 
Hyper processor. 
 
6.2.3.4 GSH Affinity Chromatography 
GSH affinity chromatography is based on the high affinity of GST to GSH. Beads coated 
with GSH were used in a gravity flow column (Biorad). The target protein, fused with a 
GST-tag, was bound to GSH-beads and equilibrated with Lysis Buffer. After approximately 
3 hours of incubation at 4 °C, the sample was poured into a gravity flow column. The 
column was then washed with 200 ml Lysis Buffer. For on-column cleavage, beads were 
resuspended in 15 ml Lysis Buffer supplemented with PreScission protease and incubated 
at 4 °C overnight. The flow-through then contained the target protein cleaved from its 
affinity tag, which stays bound to the beads, as do uncleaved target protein and 
PreScission protease (expressed as a GST-fusion protein). Wash fractions, samples of 
the beads before and after on-column cleavage as well as flow-through fractions were 
analyzed by SDS-PAGE to track the purification process. Flow-through fractions 
containing target protein were pooled for subsequent purification steps. 
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6.2.3.5 Ion Exchange Chromatography 
Ion exchange chromatography is a method used for separation of charged particles. To 
this end charged groups are covalently bound to the column material. In an aqueous 
solution the charged groups are surrounded by ions of the opposite charge. When the 
solution has a low ionic strength, molecules can be immobilized on the column that only 
have weak binding properties. By increasing the ionic strength, the weaker binding 
molecules are eluted. The mPRPF39 sample was loaded in the minimal buffer containing 
no salt. After mPRPF39 was bound to the column it was washed with 20 column volumes 
of minimal buffer and the eluted with a 20 column volume NaCl gradient from 0 to 600 mM 
NaCl. 
 
6.2.3.6 Size Exclusion Chromatography (SEC) 
During a SEC proteins are separated according to their hydrodynamic volume. Under the 
condition that the protein does not interact with the stationary phase large molecules will 
run through an SEC column faster than small molecules because they cannot penetrate 
the beads of the stationary phase and will therefore have to pass a smaller volume and 
elute earlier than small molecules which penetrate the beads. 
A Superdex 200 10/300 increase column was equilibrated with SEC buffer and an injection 
volume of the protein solution recommended by the manufacturer was loaded onto the 
column. The protein elution was tracked by measuring the UV absorption at 280 nm and 
260 nm. The fractions with the highest protein concentration and purity are selected and 
concentrated with a filter with an appropriate cut off through ultrafiltration at 4000 g.  
 
6.2.3.7 Protein Purification 
Proteins bearing an N-terminal, PreScission-cleavable GST-tag were produced in E. coli 
BL21 pLys cells in LB-medium overnight at 18 °C after induction at OD ~ 0.6 with 0.5 mM 
IPTG. The following steps were performed at 4 °C. Cells were resuspended in 
solubilization buffer (50 mM Tris/HCl pH 8.4, 1 mM DTT) and lyzed by sonication. Cell 
debris was separated from the soluble fraction by centrifugation for 45 minutes at 
55,900 x g in an Avanti J-26 XP centrifuge (Beckman Coulter). Target proteins were 
captured on glutathione agarose and washed with solubilization buffer. The GST-tag was 
cleaved with 1:50 PreScission on the column overnight and for the mutant mPRPF39 
variants for 4 h. The flow-through was collected, subjected to a 1mlQ column followed by 
concentration and size exclusion chromatography (SEC) in solubilization buffer using a 
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Superdex 200 column (GE Healthcare). Peak fractions were analyzed by SDS-PAGE. 
Fractions containing the target protein were pooled, concentrated, and shock-frozen in 
liquid nitrogen.  
Transformed E. coli Rosetta2 DE3 were cultured in minimal media containing 
selenomethionine (Van Duyne 1993) and at an OD ~ 0.6, protein expression was induced 
by addition of 0.5 mM IPTG. Purification was carried out as described above for mPrp39wt, 
except that all buffers contained 2 mM DTT. 
 
6.2.3.8 Differential Scanning Fluorimetry (DSF) 
Identifying conditions in which protein samples are stable over long periods of time and 
are prevented to aggregate or denature is extremely helpful for experiments involving 
analytical and biophysical techniques that require high protein concentrations. 
Many factors can influence protein stability such as: buffers (chemical composition as well 
as pH), salts and detergents whose interactions with the protein are non-specific. Ligands, 
which bind proteins at specific sites, may also produce noticeable effects as protein 
stabilizers. The stability of a protein is characterized by the Gibbs free energy of unfolding, 
ΔGu, which is temperature-dependent. The stability of most proteins decreases as the 
temperature increases, meaning that ΔGu decreases and reaches zero at the equilibrium 
point where the concentrations of folded and unfolded protein are equal. At this equilibrium 
point, the temperature is called melting temperature (Tm). 
DSF monitors the thermal unfolding of proteins in the presence of a fluorescent dye that 
is highly fluorescent in non-polar environment compared to aqueous solution where the 
fluorescence is quenched. Practically, DSF is performed using a real-time PCR instrument 
and monitors the fluorescence intensity of the dye as a function of the temperature. Upon 
protein unfolding by thermal denaturation, the dye preferentially binds to the now exposed 
hydrophobic patches of the protein and the fluorescence intensity increases. This 
generates a sigmoidal curve that can be described as a two-state transition and the Tm 
can be extracted from the curve by determining the first derivative. 
DSF experiments were done in a 96-well plate in a plate reader combined with a 
thermocycler (Stratagene Mx3005P). In order to determine a suitable protein 
concentration, purified protein was diluted to series of concentrations varying from 1 μM 
to 10 μM in the final purification buffer supplemented with 10×SYPRO orange (1:500 
dilution of the stock) in a total volume of 20 μl and pipetted into a 96-well plate. The 
temperature was increased from 25°C to 95°C and the fluorescence emission was 
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monitored in 1 °C increments with hold steps of 30 second between reads. The 
fluorescence intensity was then plotted as a function of temperature. The protein 
concentration that showed a clear sigmoidal curve was chosen for buffer optimization and 
compound screens. Different buffer compositions and compounds were tested for their 
stabilizing effect on the protein at the defined protein concentration. The sigmoidal curve 
from each condition was normalized and corrected for the background signal of the 
fluorophore in the buffer. The inflection points of the curves, representing the thermal 
melting temperature of the protein in the respective conditions, were compared. 
 
6.2.3.9 Limited Proteolysis 
Limited proteolysis experiments can inform on conformational features of proteins. In a 
number of studies, it has been demonstrated that the sites of limited proteolysis along the 
polypeptide chain of a protein are characterized by enhanced backbone flexibility, implying 
that proteolytic probes can pinpoint the sites of local unfolding in a protein chain (Fontana 
2004). This means that only flexible regions of the target protein such as disordered 
termini, exposed loops, or flexible domain linkers can be cleaved. Removing such flexible 
parts from a protein generates more compact and conformationally homogeneous 
molecules or compact single domains. These proteolytic fragments or domains of a protein 
may crystallize more readily or form better diffracting crystals than the intact protein. 
Limited proteolysis has been widely used to define the boundaries of single domains or a 
set of tightly interacting domains in a molecule by trimming its flexible and unstructured 
parts and, thus, increasing its propensity to crystallization. The increased likelihood of a 
domain or a smaller set of domains to yield structural information can be explained, in a 
way, by the observation that large proteins are often composed of many individual 
domains. The conformational heterogeneity that results from motion between such 
domains is a severe impediment to crystallization. 
The generation of domains by limited proteolysis relies directly on the tertiary structure of 
the protein under investigation and provides much firmer evidence for their existence than 
that provided by sequence homology and secondary structure predictions. 
In practice, limited proteolysis is achieved by dilution of the proteases sufficiently so that 
they will only digest the most accessible and flexible regions of the protein substrate 
leaving the domains intact. Initially, the protein substrate should be digested with various 
proteases to establish which conditions are optimal for generating a protease-resistant 
domain. 
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To search for stable fragments, full-length mPRPF39 was treated with various proteases. 
For each reaction, 9 μg of protein were incubated with increasing amounts (0.004, 0.04 
and 0.4 μg) of protease at 20 ºC for 30 minutes in buffer containing 10 mM Tris/HCl, pH 
7.5, 150 mM NaCl, 2 mM DTT. The reactions were stopped by addition of 10 μl SDS-
PAGE loading buffer. Half of each sample was separated by SDS-PAGE and bands were 
analyzed by tryptic mass spectrometric fingerprinting  
 
6.2.3.10 Band Preparation for Mass Spectrometry 
Mass spectrometry was used to analyze the protein fragments produced by limited 
proteolysis and to test for selenomethionine (SeMet) incorporation. The proteins/protein 
fragments were separated by SDS-PAGE and stained with Coomassie staining solution 
Bands of interest were excised and proteins were digested in-gel with trypsin and extracted 
as previously described by Shevchenko et al., 1996. Tryptic fragments were supplied to 
Christoph Weise, FU Berlin, for mass spectrometry analysis. 
 
6.2.3.11 Size exclusion with multi-angle light scattering (SEC-MALS) 
SEC-MALS experiment was performed at 18 °C with buffer containing 50 mM Tris/HCl, pH 
8.4, 300 mM NaCl and 0.02% NaN3. 80 µg of mPRPF39wt or of mPRPF39 variants was 
loaded onto a Superdex200 increase 10/300 column (GE Healthcare) that was coupled to 
a miniDAWN TREOS three‑angle light scattering detector (Wyatt Technology) in 
combination with a RefractoMax520 refractive index detector. For calculation of the 
molecular mass, protein concentrations were determined from the differential refractive 
index with a specific refractive index increment (dn/dc) of 0.185 ml/g. Data were analyzed 
with the ASTRA 6.1.4.25 software (Wyatt Technology). 
 
6.2.3.12 In Vitro Splicing  
Splicing active nuclear extracts were prepared according to (Dignam 1983), except 
HEK293T cells harvested at ca. 80 % confluency were used. For splicing analysis, m7G-
capped RNAs were produced by in vitro transcription using linearized plasmid as template. 
In vitro splicing assays were performed in 52% HeLa nuclear extract, incubating 1 fmol of 
pre-mRNA and 5 μg of protein or equivalent volume of purification buffer per 25-μl reaction 
mixture under splicing conditions, as described previously (Dignam 1983). The reaction 
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was stopped after 1 h by proteinase K treatment followed by RNA extraction. 20% of the 
RNA was reverse-transcribed and analyzed by RT-PCR. 
 
6.2.4 Crystallographic methods 
6.2.4.1 Basic Principles of X-ray Crystallography 
The main goal in X-ray crystallography is to derive the three-dimensional structure of a 
given protein, other biomacromolecules or complex based on a set of X-ray scattered 
intensities measured at different directions in space. This process can be divided in three 
basic steps. The first step is to obtain a protein crystal. The scattering of X-rays by a single 
protein molecule is extremely weak and still not possible to detect routinely. However, the 
periodic arrangement of proteins inside a crystal creates interference effects, which greatly 
enhance the intensity of the scattered X-rays in particular directions allowing them to be 
measured. In the second step, the crystal is exposed to an intense monochromatic beam 
of X-rays generating a distribution of scattered radiation in different directions in spaces, 
known as the diffraction pattern. A detector records the snapshots of the scattered X-rays 
as the crystal is rotated. The complete pattern is then retrieved based on the measured 
snapshots and symmetry considerations. 
The third step consists of the determination of a structural model from the computational 
analysis of the diffraction pattern. Firstly, an electron density map is derived from the 
diffraction pattern. Then, the initially derived electron density is fitted with a structural 
model, which describes the position of atoms inside a protein. The structural model is 
refined by repeating this process iteratively until some statistical quantities related to the 
goodness of fit achieve a certain desired value. 
 
6.2.4.2 General Crystallography Setup 
To identify initial crystallization conditions, different commercially available crystallization 
reagents were screened in 96-well MRC plates by sitting drop vapor diffusion technique. 
Drops of 200 nl (100 nl protein solution + 100 nl reservoir) were dispensed using a 
Cartesian liquid dispensing robot with 8 channels. 
Initial hits were usually refined by manual setups in a 24-well format. Commercial additive 
screens were routinely tested to improve crystallization conditions. 
 
  




Native crystals were obtained by the sitting-drop vapor-diffusion method at 4 °C with a 
reservoir solution composed of 0.1 M Bis-Tris-propane/HCl pH 6.5 and 1.8 M sodium 
acetate. Selenomethionine-labeled crystals were obtained by the hanging-drop method at 
18 °C with a reservoir solution composed of 0.1 M Bis-Tris-propane/HCl pH 6.5, 1.6 M 
sodium acetate and 0.75 mM tris(2-carboxyethyl)phosphine. Crystals were cryo-protected 
with a solution composed of 80% mother liquor and 20% (v/v) propylenglycole and 
subsequently flash-cooled in liquid nitrogen.  
 
6.2.4.4 Diffraction Data Collection, Structure Determination and Refinement 
Synchrotron diffraction data were collected at the beamlines the MX Joint Berlin laboratory 
at BESSY (Berlin, Germany) and P14-2 of PETRA III (Deutsches Elektronen Synchrotron, 
Hamburg, Germany). Diffraction data were processed with XDS (Kabsch 2010). 
Experimental phases were determined by single anomalous dispersion with the AutoSol 
routine in PHENIX (Terwilliger 2009) using Phaser (McCoy 2004) and SOLVE/RESOLVE 
(Terwilliger 2000) exploiting selenomethionine-labeled mPRP39. An initial, partial model 
of mPRPF39 was built with the program AUTOSOL in PHENIX (Terwilliger 2009). The 
structure was refined by maximum-likelihood restrained refinement using in PHENIX 
(Adams 2010, Afonine 2012) including Translation/Libration/Screw (TLS) refinement 
(Winn 2001). Model adjustment was performed with Coot (Emsley 2010). Model quality 
was evaluated with MolProbity (Chen 2010) and the JCSG validation server (Yang 2004). 
Secondary structure elements were assigned with DSSP (Kabsch and Sander 1983) and 
ALSCRIPT (Barton 1993) was used for secondary structure based sequence alignments. 
Figures were prepared using PyMOL (DeLano 2002). 
 
6.2.5 Bioinformatics 
All bioinformatics were performed by Alexander Neumann, FU Berlin. U1 RNA sequences 
were extracted from Rfam (Kalvari 2018) and NCBI (Geer 2010). Protein sequences of 
Prp39 and Prp42 homologs were extracted from NCBI and the canonical isoform was 
defined using UniProt (The UniProt 2017). RNA secondary structure predictions were 
performed using the RNAstructure Web Server (Reuter and Mathews 2010). 
ClustalOmega was used for multiple sequence alignments (Sievers 2011). Consensus 
sequences with identity threshold above 50% were calculated using SeaView v4 (Gouy 
2010). The common tree taxonomy tool from NCBI was used to create a phylogenetic tree 
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7.1 Production of Proteins 
One of the most time-consuming steps during high resolution structure-based studies is 
the production of significant amounts of pure protein suitable for crystallization. For this 
purpose, the production was optimized by adjusting different parameters in the bacterial 
expression system. Initial expression test showed that the presence of mPRPF39 seemed 
to inhibit cell growth, as the OD600 stayed constant upon induction with IPTG, showing only 
poor overexpression. 
 
Figure 16 Optimization of mPRPF39 expression. Coomassie-stained SDS-PAGE gels showing a 
test expression with GST-pulldown: A Performed in LB and auto-inducing media. The test 
expression in LB media shows much higher comparative overexpression of mPRPF39. B 
Performed in different bacterial strains. The pLysS strain showed the highest yield. C A time course 
of the expression of mPRPF39 at 18 °C and 37 °C. Expression overnight at 37 °C leads to near 
complete protein degradation. The abbreviations CE stands for whole cell extract, CL cleared 
lysate, FT for flow through, B for beads, M for marker and ON for overnight. The sizes in kDa of the 




Two different media were tested; auto-induction media and LB-Medium with IPTG 
induction (Figure 16 A), three different E. coli strains; BL21, pRare, and pLysS (Figure 16 
B), and different expression times at two different expression temperatures; 18 °C and 
24 °C (Figure 16 C). The optimal combination proved to be E. coli pLysS cells in LB-
medium with IPTG induction and expression at 18 °C overnight. 
 
7.2 Purification 
To purify the protein after expression, the cell lysate was loaded on to preequilibrated GST-
beads and a tag cleavage with PreScission was performed overnight on bead. The elution 
and wash fragments were then pooled and subjected to size exclusion. 
To optimize the amount of soluble protein and encourage homogenous running properties, 
a differential scanning fluorimetry screen was performed, to find the optimal buffer 
conditions. The analysis showed, that mPRPF39 was overall relatively stable in the chosen 
buffer with a Tm of 43 °C and all but one condition having a lower Tm. The condition A10 
(50 mM Tris/HCl, pH 8.4) increased the melting temperature slightly to 44 °C (Figure 17). 
This is not a big difference, but because the condition was very similar to the initially 
chosen buffer (50 mM Tris/HCl, pH 8.5, 400 mM NaCl, 2 mM DTT) and had no additional 
salt, this minimal buffer was used for all future purifications as a minimal buffer can be 
beneficial for crystallization. 
 
Figure 17 DSF analysis of mPRPF39. The different Tm of the screened conditions are plotted here. 
Overall the already chosen lysis buffer exhibited a comparatively high Tm. Only one condition, A10, 
showed a slightly increase Tm. For color-coding see inlet. 
After initial purification trials, the protein showed very high 260/280 values (>1.5). To 
remedy this, the elution and wash fractions after the GST-column were loaded to a 




mPRPF39 was then purified in a final step over a SEC column with the minimal buffer 
(Figure 18). 
 
Figure 18 Purification of mPRPF39. Coomassie-stained SDS-PAGE gels showing A GSH 
purification B anion exchange and C SEC of fractions 11 through 17 from the anion exchange with 
their corresponding chromatograms D and E. The molecular weight marker is shown on the left 
(sizes in kDa) and the fraction number is indicated above the lanes. The abbreviations CE stands 
for whole cell extract and CL cleared lysate, FT for flow through and B for beads. 
 
7.3 Limited proteolysis 
Flexible regions in proteins can hinder crystallization. In order to remove such regions, 
mPRPF39 was treated with different proteases. Upon elastase treatment, a stable 
fragment appears when a concentration of 0.013 µg/µl is chosen. There is still quite some 




concentrations the protein is completely digested. When mPRPF39 is treated with 
subtilisin, a stable fragment is observed only with the lowest concentration. If the subtilisin 
concentration is increased, this leads to complete degradation of the protein, similar to the 
highest concentration of chymotrypsin. However, chymotrypsin does not seem to 
significantly degrade mPRPF39 at lower concentrations. When treated with GluC, we 
observe the stable approximately 60 kDa band of mPRPF39 even at the highest protease 
concentration (Figure 19). 
 
Figure 19 Experimental definition of mPRPF39 stable fragments. Coomassie-stained SDS-PAGE 
gels showing limited proteolysis of full-length mPRPF39. The decreasing protease concentration is 
indicated by a triangle. A stable, ca. 60 kDa fragment could be obtained with all proteases but 
Chymotrypsin. C stands for undigested control protein and M for marker. 
After trypsination, the bands were subjected to mass spectrometry analysis. The total 
mass of the fragment is 66.06 kDa and, after trypsination, peptides in the core region of 
mPRPF39 could be observed. The region in which peptides were observed coincides 
nicely with the area of mPRPF39 that is predicted to be structured. Using the results from 
secondary structure predictions and mass spectrometry three additional constructs 
missing either the C- or N-terminus or both, were designed (Figure 20). 
 
Figure 20 Schematic representation of the cloned mPRPF39 constructs. Teal boxes represent 
portions of mPRPF39, pale green boxes indicate GST-tag at the appropriate terminus and the 





Both constructs missing the N-terminus could not be expressed. mPRPF39ΔC could be 
expressed in abundance without the cell growth limitation visible for the full-length 
mPRPF39. mPRPF39ΔC could be purified analog and in similar purity to the full-length 
protein (Figure 21). 
 
Figure 21 Size Exclusion of mPRPF39ΔC. Coomassie-stained SDS-PAGE gels shows the size 
exclusion of mPRPF39ΔC on a SD 200 10/300 column. The purity is comparable to that of the full-
length protein. 
 
7.4 Crystallization and Structure Determination of mPRPF39 
To obtain mPRPF39 crystals, initial screens of both constructs purified were prepared 
using a crystallization robot to facilitate testing a broad spectrum of conditions. Initial hits 
were observed for both constructs and could be successfully reproduced. The crystals 
were then tested at a synchrotron beamline (BL 14.2 Bessy, Berlin). The best diffracting 
crystal of the initial screening was of the full-length mPRPF39 and diffracted to 3.8 Å. The 
crystals overall showed high variances in diffraction quality with only about one in 20 
diffracting under 4 Å.  
To further optimize the crystallization conditions, additive screening, micro seeding and 
different temperatures were tried. Addition of poly(ethylene glycol) methyl ether 5000 to 
3% proved to be beneficial to the crystal morphology of mPRPF39ΔC, however the 
diffraction could not be increased by any of the tested methods. Because the full-length 
protein seemed to be more promising, the focus was mainly shifted on to mPRPF39full-length. 
Using the same crystallization conditions as at 18 ° for the full-length mPRPF39 at 4 °C 
increased the amount of well diffracting crystals with the best dataset collected at 3.3 Å. 
Several search models were used, to perform molecular replacement with the goal of 
solving the phases. We used murine CSTF-77 (PDB entry 2OND (Bai 2007)), K. lactis 
RNA14 (PDB entry 4EBA (Paulson and Tong 2012)) and also the PHYRE prediction model 
(Kelley 2015) of mPRPF39 itself. None of the models available to us at the time could be 




To address the phase problem, a SeMet derivative of mPRPF39 was used. This seemed 
promising because there are 17 SeMet per molecule spread nicely over the whole protein 
sequence. 
The SeMet mPRPF39 was expressed as described in the Materials and Methods section 
and could be purified analog to the native mPRPF39. The purity was comparable to the 
native protein and SeMet incorporation was tested by mass spectrometry (Figure 22).  
 
Figure 22 MALDI-MS of whole mPRPF39 and SeMet derivative. The upper panel shows the 
measurement for native mPRPF39 (teal) and the lower panel for SeMet mPRPF39 (orange). The 
expected mass for the full-length protein (78,335 kDa) is clearly matched and the increase in mass 
indicates full SeMet incorporation. 
The SeMet mPRPF39 crystallized in the same condition as the native protein and crystal 
quality could be improved by addition of 7.5 mM tris(2-carboxyethyl)phosphine (Figure 
23). 
 
Figure 23 mPRPF39 crystals. A Native full-length mPRPF39 crystals. B mPRPF39ΔC crystals. 
C Optimized SeMet full-length mPRPF39 crystals. 
A selenomethionyl single-wavelength anomalous diffraction (SAD) dataset diffracting to 
3.8 Å could be collected for the improved crystals. The anomalous signal itself was rather 




AutoSol from the PHENIX suite. AutoSol includes HYDD, SOLVE, Phaser and RESOLVE 
and is optimized for datasets with weak anomalous signal. In the first round of AutoSol 25 
anomalous sites could be identified. This was followed by extreme density modification 
and autobuild which was not successful. The option extreme density modification is 
recommended for low resolution structures with weak anomalous signal. When this option 
is chosen fewer cycles of density modification are performed, the thoroughness is set to 
thorough so more solutions are examined, the density of the first density-modified map is 
used as a partial model to try and find additional anomalous scatterers, a more extensive 
search for anomalous scatterers is performed (thoroughness set to thorough) and the 
minimum non-crystallographic symmetry (NCS) correlation to keep NCS is lowered. The 
extreme density modification was invaluable in providing an interpretable electron density 
map. 
α-helices were manually fitted into the resulting density to obtain an initial model and then 
the preliminary model was used as input model for another round of AutoSol. With the 
additional information of the model, 27 sites could be identified and phase extension to 3.3 
Å was performed with the native dataset. After the second iteration, a partial model was 
obtained by autobuild. However only the placement and the direction of the α-helices was 
correct, the sequence had to be extensively corrected manually. 
 
Figure 24 Electron density quality in mPRPF39. A 2mFoFc electron density drawn as pale-green 
mesh contoured at 1.0 σ. α-helix α1A of HAT repeat number 1 is shown in teal as stick 
representation. B Anomalous difference Fourier map contoured at the 3σ level. The placement of 
SeMets allowed sequence assignment. 
Overall the electron density was of excellent quality for the resolution and allowed for 




unit and the model was built independently in both NCS related protein chains. The current 
structure includes in total 52 α-helices and 1019 residues. After placing the poly-alanine 
α-helices in the density, the anomalous density was used to place methionines (Figure 24 
B) and, subsequently the sequence in the α-helices harboring a methionine residue. The 
structure of the RNA 14 dimer (Paulson 2012) was used to verify the sequence according 
to the HAT repeat motifs, assign residues in non-methionine α-helices and connect the α-
helices. For the refinement, strict NCS were used with secondary structure restraints and 
3 TLS groups per monomer. For data collection and refinement statistics see Table 6. 
 
Table 6 Crystallographic data collection and model refinement statistics. 
Data Collection SeMet Native 
Wavelength [Å] 0.9763 0.9184 
Temperature [K] 100 100 
Space group C2 C2 
Unit Cell Parameters 
a, b, c [Å]; β [º] 
 
189.2, 73.0, 206.7; 112.4 
 
189.5, 72.8, 207.1; 112.5 














Intensity [I/σ(I)]  
Rmeas [%] 
CC1/2 
Wilson B value [Å2] 




















Resolution range [Å ]a  50.00 – 3.30 (3.42 – 3.30) 
Reflections a  38901 (3770) 
Rwork 
Rfree 
 0.246 (0.443) 
0.293 (0.443) 




Mean B-factor [Å2]b  154.5 
RMSD from Target Geometry 
Bond Lengths [Å] 




Validation Statistics c 
Ramachandran Plot 
Residues in Allowed Regions [%] 
Residues in Favored Regions [%] 
MOLPROBITY scoreb 







a Data for the highest resolution shell in parentheses 
b Calculated with MOLPROBITY (Chen 2010) 





7.5 Overall Structure of mPRPF39 
The final structure shows mPRPF39 to be arranged as a dimer. Even though the protein 
is purely α-helical, being made up of 12 pairs of anti-parallel α-helices arranged as HAT 
repeats, it can be divided into three distinct subdomains (Figure 25). 
 
Figure 25 Overall structure of mPRPF39. A Schematic representation of the domain architecture 
of mPRPF39 comprising of 665 amino acid residues. The HAT-NTD is colored in a gradient from 
yellow to orange, the HAT-CTD in teal to aqua and the linker is colored in pale green. Regions that 
are unstructured are indicated as dotted lines. B Dimer arrangement of mPRPF39 drawn in cartoon 
representation. One monomer is drawn in gray and the second monomer according to the color 
gradient as described in panel A. HAT domains are numbered 1 through 12 starting at the N-
terminus. C View is rotated by 90º and in addition the surface is shown for the second monomer. 
An N-terminal domain (HAT-NTD) consisting of 5 HAT repeats, a C-terminal domain (HAT-
CTD) comprised of 7 HAT repeats, and a linker region. The linker region is composed of 
a short and a long curved α-helix (Lα1 and Lα2) and an unstructured region (residues 275 
to 294) that connect the α-helices. There was also no interpretable electron density 




protein were predicted to be unstructured, leading us to the conclusion, that the lack of 
electron density is due to their flexibility. The areas lacking density were not degraded, as 
mass spectrometry shows the dissolved crystals to be of the expected size of the full-
length protein (Figure 26). 
 
Figure 26 MALDI-MS of mPRPF39 crystals. The upper panel shows the measurement for SeMet 
full-length mPRPF39 crystals dissolved in water (pale green) and the lower panel for SeMet 
mPRPF39 (teal). The dissolved crystals show a mass almost identical to the control protein 
measurement. This indicates that the protein is not degraded in the crystals but that the undefined 
N- and C-termini and loop region are flexible. 
Both mPRPF39 molecules are arranged in an anti-parallel manner as a homodimer in the 
crystal structure (Figure 25). The dimerization is mediated over the concave surfaces of 
the HAT-CTDs with the HAT-NTDs not playing a role in the dimerization. In the side view, 
the dimer appears to be bridge shaped with the HAT-NTDs making up the base and the 
HAT-CTDs the arch (Figure 25). The dimerization surface spans approximately 1536 Å2 
of buried surface for each molecule and the dimerization is predicted to be stable in 
solution by the PISA server (Krissinel and Henrick 2007). 
To further investigate whether the dimer is stable in solution and not a crystallographic 
artefact, SEC-MALS experiments were performed to determine the molecular weight of 
mPRPF39. The SEC-MALS analysis shows the protein to have a molecular weight of 157 
kDa confirming stable dimerization of mPRPF39 in solution (Figure 27). The dimer seems 
to be remarkably stable, still showing dimeric behavior under high salt conditions (900 mM 
NaCl) (Figure 27). The slight difference in retention volume observed between the 







Figure 27 Analysis of the oligomeric state of mPRPF39 by SEC-MALS. Solid lines correspond to 
the absorbance measured at 280 nm for mPRPF39. For color-coding see inlet. Dashed lines 
correspond to the average molecular weight (MW) values of mPRPF39. mPRPF39wt shows dimeric 
behavior. Even at high salt concentrations, the dimer cannot be disrupted, however the elution 
profile is slightly shifted caused by the high salt concentration. 
Interestingly when the C-terminally truncated version of mPRPF39 was analyzed via SEC-
MALS, three peaks corresponding to different molecular weights could be observed. The 
first peak is of inhomogeneous size distributed around 260 kDa, the second peak shows 
a size of 160 kDa, corresponding to the dimer size and the small third peak has a molecular 
weight of 84.6 kDa, close to the monomer size (Figure 28). 
 
Figure 28 Analysis of the oligomeric state of mPRPF39ΔC by SEC-MALS. Solid lines correspond to 
the absorbance measured at 280 nm. Dashed lines correspond to the average MW values of 
mPRPF39 and its variants in different oligomeric states. mPRPF39ΔC shows a peak with high 
molecular weight not clearly assignable to an oligomeric state, a dimeric species and small amounts 
of monomeric species. 
This is a hint, that the dimerization is stabilized over the unstructured C-terminus but 
truncating the C-terminus is not sufficient to completely abolish dimerization. 
In addition to the SEC-MALS experiments, a Flag-IP experiment was also performed. In 
this experimental setup, HEK293T cells were transfected with GFP-mPRPF39 and either 




to α-FLAG beads and western blotting. The results demonstrate that GFP-mPRPF39 can 
only be co-precipitated in the presence of FLAG-mPRPF39 confirming dimerization 
(Figure 29). With this experiment it could be shown that not only in crystallo and in solution, 
but also in cellular environment mPRPF39 forms a dimer. This is especially interesting, 
because it offers a possible explanation for how the absence of a Prp42 homolog can be 
compensated in Metazoa. 
 
Figure 29 Co-Immunoprecipitation of differently tagged mPRPF39. Western blot of an αFlag-IP of 
Flag- and GFP-mPRPF39. GFP-mPRPF39 can only be pulled down in the presence of Flag-
mPRPF39. Asterisk indicates an unspecific band. 
 
7.6 The Homodimer Interface of mPRPF39 
To investigate whether the homodimerization is indeed as crucial as it seems, the aim was 
to disrupt the dimerization by single point mutation. To find suitable candidates for mutation 
several properties of the protein were taken into consideration. First, the residues in the 
dimerization interface were determined and only these were considered for mutation 
(Figure 30 A). Then the conservation of the surface residues was analyzed with the help 
of the ConSurf server (Ashkenazy 2016). Analysis of the mPRPF39 HAT-CTD shows that 
there is a high degree of conservation in residues located in the dimerization interface of 
mPRPF39 further cementing the physiological importance of the homodimerization and 
indicating that the homodimerization is conserved in metazoan (Figure 30 B). Next, the 
electrostatic potential of mPRPF39 was calculated and plotted on the surface (Figure 30 
C). A very distinct charge distribution pattern can be observed in the HAT-CTD. There are 
two distinct patches, one with a strong positive and one with a strong negative charge. 
Interestingly, in the dimer structure, these patches interlock with each other, forming tow 
areas where the positive and negative patches interact with each other respectively in the 
second dimer copy. Overall it can be said that the dimerization is highly conserved among 





Figure 30 Surface analysis of mPRPF39 to find suitable candidates for mutation. A Surface 
representation of a mPRPF39 monomer. Interfacing and non-interfacing amino acid residues 
colored in teal and grey, respectively. B Amino acid residue conservation projected onto the surface 
of mPRPF39. Color-coding according to bins: bin 9, colored in magenta, contains the most 
conserved positions. Whereas bin 1 contains the most variable positions as indicated in cyan. The 
concave side of the HAT-CTD shows a distinct conserved area. C Electrostatic potential mapped 
on the surface of mPRPF39. There are two distinct positively and negatively charged patches on 
the concave side of the HAT-CTD. In panels A through C the view is rotated by 90° of the horizontal 
axis relative to Figure 25 panel B. D Zoom into the dimerization interface. Amino acid residues 
subjected to site-directed mutagenesis are indicated in light blue (mPRPF39R458D), blue 
(mPRPF39R464D), red (mPRPF39E576K/D577K) and black (mPRPF39Y536W). E Analysis of the 
oligomeric state of mPRPF39 by SEC-MALS. Average MW values as measured by MALS are given 
by the selected peaks. Solid lines correspond to the absorbance measured at 280 nm for mPRPF39 
and the variants. For color-coding see inlet. Dashed lines correspond to the MW values of 
mPRPF39 and its variants in different oligomeric states. mPRPF39wt and mPRPF39Y536W show 
dimeric behavior, mPRPF39R458D shows a mixture of monomeric and intermediate species, while 
dimerization is completely abolished for mPRPF39R464D and mPRPF39E576K/D577K. 
For mutagenesis the amino acid residues were selected based on their location in the 
interface, sequence conservation and charge. The single point mutations mPRPF39R458D, 
mPRPF39R464D, mPRPF39Y536W and the double mutant mPRPF39E576K/D577K were chosen 
for further analysis. Two highly conserved residues in the positive patch (R458 and R464) 
were mutated to create a reversal of charge. Y536, as the only aromatic residue to be 
found in the interface, was mutated to a more bulky tryptophan residue. The idea here was 
to cause steric hindrance of dimerization. The last mutation performed was the double 
mutation of E576 and D577. These are highly conserved residues in the negative patch 




The dimerization properties of all four mutants was analyzed with SEC-MALS in 
comparison to the wild type mPRPF39. Mutation of Y536 to tryptophan seems to have no 
effect on dimerization. The mutant mPRPF39R458D shows a mixture of monomeric species 
and species with an intermediate molecular weight. However, mPRPF39R464D in the 
positively charged patch and mPRPF39E576K/D577K could be clearly identified as monomers 
compared to mPRPF39wt (Figure 30 E). These results confirm that the dimerization is 
mediated over interactions between the charged areas in the HAT-CTD of mPRPF39. 
 
7.7 Functional relevance of mPRPF39 homodimerization 
To test whether the homodimerization has a functional relevance, in vitro splicing assays 
were performed with both wild type mPRPF39 and monomeric mPRPF39. Both the mutant 
mPRPF39R464D and mPRPF39E576K/D577K are monomeric in solution. For further studies 
mPRPF39R464D was chosen because in contrast to the double mutant mPRPF39E576K/D577K 
it is a single point mutant and thus has less differences compared to the wild type 
mPRPF39 on a protein level. 
 
Figure 31 Influence of mPRPF39 dimerization on splicing. A Schematic representation of the 
modified 3 exon 2 intron Adml construct used for in vitro splicing. B Exemplary gel of RT-PCR of in 
vitro splicing reaction showing buffer mPRPF39wt and mPRPF39R464D treated samples. Samples 
treated with wild type protein show slightly elevated splicing and mutant treated samples show 
significantly reduced splicing. The experiment was performed three times with each time freshly 
prepared splicing active nuclear extract in technical triplicates. The asterisk indicates a non-specific 
band. C Quantification of 4 experiments performed in triplicates on four different days. Errors shown 
as standard deviation, a one sample T-test was performed, and p values shown in C (*≤0.05, 
**≤0.01). 
For the in vitro splicing experiments a small-scale production of splicing active nuclear 




under splicing conditions with pre-mRNA and with either purification buffer as a control, 
mPRPF39wt or mPRPF39R464D. A modified Adml pre-mRNA construct was used containing 
three exons (Figure 31). After 30 minutes of splicing, the RNA was purified and an RT-
PCR was performed. There are three bands visible, the unspliced pre-mRNA, a spliced 
three-exon product and a shorter spliced product with the second exon skipped. Only trace 
amounts of the three-exon product are visible on the gel, however, the two-exon product 
shows clear differences in abundance (Figure 31). 
Addition of mPRPF39wt to the splicing reaction shows a trend toward higher splicing 
efficiency when compared to samples treated with the purification buffer. However, this 
effect is not significant. This suggests that the prepared nuclear extracts may already 
contain sufficient amounts of PRPF39 and that the addition of more PRPF39 does not 
affect splicing so strongly in this setup. The samples treated with mPRPF39R464D show 
significantly reduced splicing levels compared to both samples incubated with mPRPF39wt 
and buffer (Figure 31). This indicates, that monomeric mPRPF39 is not functional in 
splicing and is able to partially displace the already present and functional PRPF39 in 
nuclear extracts.  
 
7.8 mprpf39 is an NMD Target 
The previous experiment showed, that reducing or increasing the level of functional 
mPRPF39 homodimer can be used to control splicing efficiency. This is especially 
interesting, because mPRPF39 has an alternative exon which contains a premature stop 
codon (Figure 32).  
 
Figure 32 Alternative splicing in mprpf39. Schematic representation of alternative splicing in 
mPRPF39 with resulting mRNA and protein isoforms. An alternative exon (orange) can either be 
included or excluded. When it is excluded the mRNA can be translated to mPRPF39. If the 
alternative exon is included a premature stop codon is introduced which may lead to NMD. Red 
arrows indicate location of primers used for RT-PCR 
Premature stop codons usually lead to NMD. This means that the inclusion of the 
alternative exon could act as a regulator for the mPRPF39 levels. The alternative exon 
and its flanking region are strongly conserved between mouse and human (Figure 33) 





Figure 33 Conservation of the alternative exon and flanking exons between mouse and human. 
Alignment of the alternatively spliced region of mPRPF39 mRNA to hPRPF39 mRNA. The region 
is almost completely conserved with no sequence changes in the splice site. Identical nt are marked 
with an asterisk. Annotated exons are shown in capitals highlighted in pale-green; the middle exon 
is alternative. 
RNA sequencing in murine T-cells shows, that the alternative exon is included to 19% in 
naïve and to 50% in memory T-cells. This could be validated by RT-PCR (Figure 34). 
Analysis of different tissues shows that the alternative exon is included in a differential 
manner as well, with especially high inclusion levels in testis and low levels in lymph node 
(Figure 34). 
 
Figure 34 prpf39 alternative exon inclusion is regulated in a cell type and tissue specific manner. 
A Representative validation of RNA-seq results by RT-PCR. B Quantification of validation as shown 
in A. PSI values represent means ± standard deviations for four independent experiments. C 
Exemplary gel of RT-PCR in different murine tissues. Results of quantification of experiments 
performed with samples from three individual mice are shown below the respective lanes. Percent 




The fact that the alternative exon could be detected at all in mRNA suggests, that it is not 
a strong NMD target. To determine whether or not inclusion of the alternative exon leads 
to degradation, murine and human T-cell lines, EL4 and Jsl1 respectively, were treated 
with Cycloheximide (CHX). CHX inhibits translation and, because NMD is strongly coupled 
to translation, CHX treatment also acts to block NMD. Indeed, RT-PCR shows that cells 




Figure 35 prpf39 is an NMD target. Analysis of mprpf39 (pre-)mRNAs in mouse EL4 cells (A, B) 
and human Jsl1 cells (C, D). Left – representative RT-PCR analyses; right – quantification. 
DMSO/CHX – DMSO/cycloheximide-treated samples. In the CHX treated cells, an accumulation of 
the transcript containing the alternative exon can be seen, indicating that this isoform is an NMD-
target. Values represent means ± standard deviations of three independent experiments. 
Significance was estimated via a one-sample T-test (* – p ≤0.05, ** – p ≤0.01). 
 
7.9 Comparison of mPRPF39 to yPrp39 and yPrp42 
Monomeric mPRPF39 has an inhibiting effect on splicing and thus demonstrates that the 
mPRPF39 homodimer might substitute the yPrp39/yPrp42 heterodimer observed in yeast. 
To further investigate this, the mPRPF39 homodimer was compared with the heterodimer 
as seen in the cryo-EM structure of the yeast U1 snRNP (Li 2017). The cryo-EM structure 
shows yPrp39 and yPrp42 to be modeled into the electron density as a heterodimer. This 
heterodimer acts as an interaction hub for various alternative splicing factors, connecting 
them to the core U1 snRNP over the heterodimer. On a primary sequence level mPRPF39 
shows 22% identity to yPrp39 and 23% identity to yPrp42 (Li 2017).  
A DALI search (Holm and Rosenstrom 2010) was performed with the mPRPF39 protein 
coordinates for structural comparison. Tentatively, it was expected to find the yPrp39 
homolog as the most similar structure, but surprisingly the structurally closest neighbors 




homolog RNA14 (PDB entry 4EBA, (Paulson and Tong 2012)) and human SART3 (PDB 
entry 5JPZ (Grazette 2016)) (Table 7). 
 
Table 7 Most closely related structures of mPRPF39 identified by Dali search (Holm and 
Rosenstrom 2010). 
PDB RMSD [Å] sequence 
identity [%] 
Z-score Protein Lit. 
2OOE 4.9 18 29.9 CSTF-77 (Bai 2007) 
5JPZ 5.5 17 27.5 SART3 (Grazette 2016) 
4EBA 5.7 15 27.3 RNA14 
(Paulson and Tong 
2012) 
5UZ5 4.5 19 25.7 Prp42 (Li 2017) 
5UZ5 7.6 6 20.3 Prp39 (Li 2017) 
 
Interestingly, the structurally closest neighbor among the snRNP associated proteins was 
not yPrp39 (PDB entry 5UZ5, (Li 2017)) with an RMSD of 7.6 Å, but yPrp42 from the same 
structure with an RMSD of 4.5 Å. To help understand the relation of all three proteins to 
each other, especially under the aspect of how the homodimer could functionally substitute 
the heterodimer, these proteins were analyzed in more detail. 
 
Figure 36 Schematic representation of the domain architecture of mPRPF39, yPrp39 and yPrp42. 
The HAT-NTD is colored in a gradient from yellow to orange, the HAT-CTD in teal to aqua, the 
linker is colored in pale green and the CTD in pale yellow. Regions that are unstructured are 
indicated as dotted lines. 
All three proteins have the same overall composition. They all have a HAT-NTD and a 





Figure 37 Structure-based alignment of mPRPF39 and yPrp42 (PDB entry 5UZ5(Li 2017)). The 
secondary structure elements of mPRPF39 and yPrp42 are shown above and below the alignment, 
respectively. α-helices are depicted as cylinders, β-strands as arrows. Slanted lines indicate 
sections of mPRPF39 and yPrp42, which are not included in the crystal structures. Secondary 
structure elements are colored by domain affiliation; mPRPF39 – HAT-NTD, orange; linker, pale-
green; HAT-CTD, teal; yPrp42 – HAT-NTD, light-gray; linker, gray; HAT-CTD, dark-gray. Colored 
triangles indicate the positions of residues mutated in the homodimer interface of mPrp39. Color-
coding: mPRPF39R458D and mPRPF39R464D, blue; mPRPF39Y536W, black; mPRPF39E576K/D577K, red. 
 
At a first glance, the most distinct differences are to be seen in the shortened linker region 
and C-terminal extension of yPrp39. While the HAT-NTDs of mPRPF39 and yPrp42 
consist of 10 α-helices arranged as HAT-repeats, the HAT-NTD of yPrp39 is made up of 





Figure 38 Structure-based alignment of mPRPF39 and yPrp39 (PDB entry 5UZ5(Li 2017)). The 
secondary structure elements of mPRPF39 and yPrp39 are shown above and below the alignment, 
respectively. α-helices are depicted as cylinders, β-strands as arrows. Slanted lines indicate 
sections of mPRPF39 and yPrp39, which are not defined in the structures. Secondary structure 
elements are colored by domain affiliation; mPRPF39 – HAT-NTD, orange; linker, pale-green; HAT-
CTD, teal; yPrp39 – HAT-NTD, light-gray; linker, gray; HAT-CTD, dark-gray. Colored triangles 
indicate the positions of residues mutated in the homodimer interface of mPRPF39. Color-coding: 
mPRPF39R458D and mPRPF39R464D, blue; mPRPF39Y536W, black; mPRPF39E576K/D577K, red. 
There is no observable density for the first 42 amino acid residues in the cryo-EM structure. 




helix in the N-terminus corresponding to the missing α-helix. Most likely the local resolution 
did not allow modeling the α-helix. 
Large differences can be observed in the linker region of mPRPF39, yPrp39 and yPrp42. 
The murine structure shows the linker region to be an arrangement of three α-helices with 
a dominating 28 amino acid residue long α-helix (Lα3 in Figure 37). The long linker α-helix 
is present in all three proteins but is vastly shortened in both yPrp39 and yPrp42. 
Moreover, the yPrp42 linker consists of only two α-helices and in the yPrp39 linker region 
no perpendicular α-helix whatsoever is to be found (Figure 37 and Figure 38). The HAT-
CTDs of all three proteins are composed of 14 α-helices each, arranged in 7 HAT repeats. 
Even though the overall architecture of the HAT domains is similar, on average the loop 
regions connecting the α-helices are longer on both yeast proteins. For example, the linker 
that connects the α-helices of the 9th HAT repeat in both yPrp39 and yPrp42 is highly 
elongated and creates an additional interaction platform for dimerization (Figure 37, 
Figure 38 and Figure 39).The linker between HAT repeat 9 and 10 in yPrp39 is also longer 
compared to mPRPF39. As a result of the elongation, it extends into the convex side of 
the CTD. 
 
Figure 39 Interaction surface between Prp(f)39 variants and yPrp42. Cartoon representation of the 
mPRPF39 homodimer (A) and the yPrp39/yPrp42 heterodimer (B). yPrp42 (light orange) and 
yPrp39 (light orange) show elongated linkers between the HAT α-helices compared to mPRPF39 
(teal). This creates additional interfacing surfaces in the yeast heterodimer highlighted in orange 
and by a circle. 
Beside the central HAT repeat containing domains, both mPrp39 and yPrp39 have N-
terminal as well as C-terminal extensions in their amino acid sequence. While in the crystal 
structure of mPrp39 these extensions could not be resolved in the electron density, the C-
terminal domain (CTD) of yPrp39 is structured (Figure 36 and Figure 37). However, we 
cannot exclude that the C-terminal extension of mPrp39 gets structured in the context of 
U1snRNP assembly and hence might act in protein-protein interactions. 
The similar domain architecture of mPRPF39 to yPrp39 as well as yPrp42 makes the 




yPrp39/yPrp42. However, there are notable differences. In both systems the dimerization 
is mediated by their respective HAT-CTDs. The mPRPF39 homodimer shows lower 
curvature in its HAT-CTD leading to an overall more elongated dimer compared to the 
yPrp39/yPrp42 heterodimer (Figure 40). When superimposing mPRPF39 with either 
yPrp39 or yPrp42, the HAT-NTDs align better compared to the HAT-CTDs (Figure 40). 
The lower degree of curvature observed for the murine homodimer causes the HAT-NTD 
of the second monomer to slap out and this leads to a spatial location far away from its 
corresonding HAT-NTD in the superimposition. 
 
Figure 40 Structural comparison of mPRPF39 and yPrp39 as well as yPrp42 structures. 
A mPRPF39 homodimer shown in ribbon representation. mPRPF39 monomers are colored in deep 
teal and pale green. The dimensions of the dimer are indicated in Å. B yPrp42/yPrp39 heterodimer 
shown in ribbon representation. yPrp42 is colored in dark grey and yPrp39 in light grey. The 
dimensions of the dimer are indicated in Å.  
 
The interface of yPrp39 and yPrp42 is dominated by hydrophobic interactions. This is in 
contrast to the mPRPF39 homodimer, where salt-bridges form the most important 
dimerization contacts. The only salt-bridge observed in the yeast heterodimer is between 
the yPrp39 CTD and the yPrp42 HAT-NTD. 
Interestingly, mPRPF39 does not only show the patch of conservation on the concave side 
of the HAT-CTD but also on the concave side of the HAT-NTD (Figure 41). Incidentally 
this region is also of high relevance in the yeast system. The conserved patch in the HAT-
NTD corresponds to the area that serves as a binding module for core U1 snRNP proteins 
to the yPrp39/yPrp42 heterodimer, indicating similar binding of the homodimer to the U1 
snRNP in metazoans. This is supported by IP-experiments showing that hPRPF39 can 





Figure 41 mPRPF39 HAT-NTD as a possible binding interface for the U1 snRNP core. A Sequence 
conservation projected onto the surface of mPRPF39. Color-coding according to bins: bin 9 
(magenta) contains the most conserved positions, bin 1 (cyan) contains the most variable positions. 
The concave side of the HAT-CTD is highly conserved. Same view as in Figure 25B rotated by 
180°. B Surface and cartoon representation of yPrp42 yU1C (PDB entry 5UZ5 (Li 2017)), 
respectively. In panels A and B the view is rotated by 180° of the vertical axis relative to Figure 25 
panel B. 
 
7.10  Coevolutionary Connection Between PRPF39 and the U1 
snRNA Length 
In the yeast cryo-EM structure, the convex side of yPrp42 has a striking positively charged 
groove that can accommodate the U1 snRNA. A kink in the SL 2 of the U1 snRNA causes 
it to fold over and bind the yPrp42 HAT-CTD (Figure 42). Because the hypothesis that 
mPRPF39 can not only substitute yPrp39 but also yPrp42 in metazoan was suggested (Li 
2017), it was interesting to investigate whether one can find a corresponding groove in 
mPRPF39 to bind the U1 snRNA. 
Upon analysis, it becomes apparent, that mPRPF39 is completely lacking a binding groove 
for RNA (Figure 42). This led to the investigation of the U1 snRNA structures in more 
detail. The yeast U1 snRNA appears to be much more complex than the murine one. Most 
notably, the SL 2 is much shorter in the murine U1snRNA lacking the part that folds over 
to bind yPrp42 in the yeast system (Figure 42).The SL 3 is strongly elongated and has a 
more complex branched structure in parts compensating for the lack of a SL 4. Interestingly 
an evolutionary study focusing on the SL 3 (Mitrovich and Guthrie 2007) suggested that 
the duplication of prp39 went along with an increasing length of SL3. However, the buried 
surface area between yPrp42 and SL 3 is much smaller than between yPrp42 and SL 2, 





Figure 42 Analysis of surface charge in connection with U1 snRNA binding. A Electrostatic potential 
mapped on the surface of yPrp42 (left) and mPRPF39 (right) in the same orientation as in Figure 
25 B, with the U1 snRNA SL 2 shown as cartoon bound to yPrp42. Only yPrp42 shows the positively 
charged grove needed to accommodate the RNA. B Schematic representations of yeast U1 snRNA 
(left) and of murine U1 snRNA (right). Characters in red indicate nts that are not conserved between 
human and murine U1 snRNA. The pale orange box highlights the elongated SL 2 in yeast 
This led us to address the question of whether the evolution from heterodimerization in 
yeast versus homodimerization in metazoan might be evolutionarily linked to the 
shortening of the U1 snRNA SL 2 and SL 3. To address this hypothesis, we decided to 
analyze the length of U1 snRNAs in different organisms. We obtained all annotated U1 
snRNA sequences from Rfam (Kalvari 2018) and calculated the median sequence length 





Figure 43 Analysis of the U1 snRNA lengths in different organisms. The number of organisms 
plotted against the median U1 snRNA length in nt. There are two populations clustering around 160 
nt and 550 nt 
The sequence lengths range between 96 and 825 nt, but most of the lengths cluster around 
two peaks. All higher eukaryotes lie on the lower end of the range clustering around a size 
of 164 nt. Members of the fungal family tend to have longer U1 snRNAs, most of them 
longer than 450 nt (Figure 43). We assume that a longer U1 snRNA corresponds to an 
elongated SL 2 and SL3. 
However, there were a few exceptions of organisms with short U1 snRNAs in fungi. 
Aspergillus fumigatus and Debaryomyces hansenii have sequence lengths of 148 and 137 
nt, respectively. When performing secondary structure predictions (Reuter and Mathews 
2010), we observed that their U1 snRNA structures resemble the human structure more 
closely with a short SL 2 and SL 3 (Figure 44 A). The Candida albicans snRNA has a 
comparatively short U1 snRNA comprised of 244 nt. It shows a surprisingly shortened SL 
3, but the yeast like SL 2 remains elongated (Figure 44 B).  
 
Figure 44 Schematic representation of U1 snRNA. SL structures are labelled. A U1 snRNA of A. 




To correlate the length of the U1 snRNP with the presence or absence of a Prp42 homolog, 
we queried NCBI for hPRPF39 as well as yPrp39 and yPrp42 homologs. The overlap 
between the organisms included in this query and the organisms with annotated U1 
snRNAs were plotted in a phylogenetic tree against the median U1 snRNA length and 
existence of a Prp42 homolog (Figure 45). 
 
Figure 45 Phylogenetic analysis of the U1 snRNA and dimerization. Phylogenetic tree of the 
organisms included in the evolutionary analysis. The fungal clade is colored orange and the 
metazoan one black. On the right side the respective median U1 snRNA nt lengths are plotted as 
bar charts. The organisms with an annotated Prp42 are colored in teal and the organisms without 
a Prp42 homolog are colored pale green. Most fungal organisms except for A. fumigatus and D. 
hansenii have a Prp42 homolog. These two organisms also have short U1 snRNAs. A list of all 
NCBI GeneIDs and NCBI sequence identifiers can be found in Table 1.  
Notably, we only find fungal organisms with Prp42 homologs (Figure 45). Interestingly the 




Debaryomyces hansenii (Figure 45). The same fungi mentioned above that have short U1 
snRNA lengths. This indicates that only in the absence of a Prp42 homolog, and thus the 
presence of a Prp39 homodimer, a short U1 snRNA SL 2 and SL 3 is observed. In contrast, 
organisms with a Prp39 and Prp42 homolog present as a heterodimer have an elongated 
SL 2 and SL 3. This strongly supports a co-evolutionary mechanism on protein and RNA 
level. 
The exon-intron structure of genes in fungal genomes was analyzed in a previous study 
(Ivashchenko 2009). This study is especially interesting, as several of the organisms found 
in the overlap of the queries performed in the course of this thesis are included in it. The 
authors find a large variance in percentage on intron containing genes spanning from as 
low as 0.7 % to as high as 97 %. The maximum number of introns contained in a gene is 
also widely distributed between 2 and 18 (Table 8). This striking difference in splicing 
complexity between the fungal organisms does not seem to correlate with either the 
genome size, total amount of chromosomes or total amount of genes. Thus, the question 
arises as to what the cause for such vast differences could be. 





Total genes] Portion of intron 
containing genes [%] 
C. glabrata 12201 13 5083 1.5 
K. lactis 10690 6 5216 2.4 
E. gossypii 8743 7 4707 4.5 
S. cervisiae 12070 16 5495 4.5 
D. hansenii 12221 7 6693 5.0 
Y. lipolytica 20502 6 5970 10.6 
S. pombe 12535 3 4909 45.6 
A. fumigatus 28810 8 9811 78.0 
N. crassa 23277 7 6483 79.6 
 
When one puts this data in relation to our analysis of the U1 snRNA length and homo- or 
heterodimerization of the Prp39/Prp42 system, it becomes apparent, that fungi with less 
complex splicing have long U1 snRNAs und a Prp39/Prp42 heterodimer, whereas fungi 




Table 9 Analysis of splicing complexity in connection with U1snRNP properties. The length of SL2 
and SL3 was estimated based on secondary structure predictions of the respective U1 snRNA. The 
length of SL2 and SL3 of S. cerevisiae is based on the structure of U1 snRNP (Li 2017). Intron 
containing genes are given in [%] and the maximal number of introns per gene is given according 



















per gene  
C. glabrata x  595 147 396 1.5 2 
K. lactis x  528 132 330 2.4 2 
E. gossypii x  483 134 276 4.5 2 
S. cervisiae x  568 122 377 4.5 2 
D. hansenii x  165 45 28 5.0 4 
Y. lipolytica x  150 43 14 10.6 4 
S. pombe  x 149 44 22 45.6 15 
A. fumigatus  x 149 46 18 78.0 18 
N. crassa  x 130 43 22 79.6 11 
 
Two irregularities to this hypothesis can be observed. D. hansenii and Y. lipolytica show 
relatively low splicing complexity but have short U1snRNAs. In the previously shown 
analysis, we only found an annotated Prp39 homolog for both of these organisms (Figure 
45). However, as they do not fit the established pattern of low complex splicing and long 
U1 snRNAs with a heterodimeric system, these two cases were investigated further. The 
yeast protein sequence of yPrp39 and yPrp42 were used to blast them both against the 
complete organism proteome of D. hansenii or Y. lipolytica. In both cases not only the 
annotated Prp39 homolog is found, but an additional second protein is found to have high 
similarity to both yPrp39 and yPrp42. This indicates a heterodimeric system in these two 
organisms, even though only a Prp39 homolog is annotated. This can be seen as 
implication that these two organisms are intermediates in which the U1 snRNA is already 
shortened, but that still have a heterodimeric Prp39/Prp42 system. This leads to slightly 
more complex splicing compared to the fungi with long U1snRNAs, with the large elevation 
in complexity only visible in fungi with a Prp39 homodimer. This is also reflected in the fact 
that, when looking at the portion of intron containing genes and the maximum number of 




complex organisms (Figure 45). These findings show the importance of the homodimeric 







In this thesis I established and optimized the expression of murine mPRPF39. Choice of 
the optimal bacterial strain, expression media and lysis buffer proved to be instrumental in 
this goal. Using limited proteolysis and mass spectrometry, a 66 kDa stable fragment of 
mPRPF39 comprising of the HAT-NTD, HAT-CTD and linker could be determined. In 
addition to the full-length protein only a C-terminally truncated mPRPF39 could be 
expressed and purified. Both of these constructs yielded crystals. However, the 
mPRPF39ΔC variant never diffracted beyond 6 Å and only the full-length construct yielded 
a final dataset at 3.3 Å. 
I solved the crystal structure of the full-length mPRPF39 protein by SeMet SAD, showing 
the protein to be arranged in a distinct three domain manner with a HAT-NTD that is 
connected via an extended linker to the HAT-CTD. In the crystal structure two mPRPF39 
molecules are arranged in the asymmetric unit as a homodimer. With SEC-MALS and Co-
IP experiments I could show that the dimerization is not only present in crystallo, but also 
in solution and in a cellular environment. 
Guided by the structure I have determined which structural elements and organizational 
aspects are fundamental for the dimerization using mutational analyses. The results 
demonstrated that the dimerization is mediated by conserved charged residues in the 
HAT-CTD. Moreover with in vitro splicing experiments I could show, that adding non-
functional monomeric mPRPF39 to the experimental setup has a detrimental effect on 
splicing. 
In conjecture with these results I analyzed the alternative splicing event of mPRPF39 
which causes the inclusion or exclusion of an alternative exon containing a stop codon. I 
could show that the inclusion and exclusion is regulated in an activation dependent and 
tissue specific manner. When the alternative exon is included, either the mprpf39 pre-
mRNA is degraded via the NMD pathway, or a non-functional mPRPF39 is translated. 
Furthermore, my work reveals an evolutionary link between the length of the U1 snRNA 
and the presence or absence of a Prp42 copy. This can be correlated to the complexity of 
splicing in an organism. 
While my work still does not clarify all the details of the precise role of PRPF39 in spicing 
in metazoans, together with the recent cryo-EM structures (Li 2017, Bai 2018, Plaschka 
2018, Zhan 2018) it provides a framework that helps us understand how a spliceosome 





8.1 The Functional Subunit of mPRPF39 is a Homodimer 
The crystal structure of mPRPF39 shows the protein to have three distinct subdomains 
arranged as a dimer. This overall protein architecture of mPRPF39 resembles the 
arrangement of other HAT repeat proteins involved in mRNA processing such as SART3 
(Grazette 2016) and RNA14 (Paulson and Tong 2012).  
SART3 plays an important role during translesion DNA synthesis and spliceosome 
recycling. SART3 is essential for formation of the U4/U6 di-snRNP (Rader and Guthrie 
2002) and as a homodimer it is essential for key interactions during this process (Huang 
2018). 
RNA14 is part of the cleavage factor IA, which is required for 3’-end processing together 
with the cleavage factor II and the polyadenylation factor I. This process, including 
cleavage and polyadenylation is an essential step in pre-mRNA processing and defects in 
the 3’-end processing can have a detrimental effect on mRNA export, stability and 
translation (Paulson and Tong 2012). Like in mPRPF39 and SART3, RNA14 has two 
distinct HAT domains, that are connected by a linker α-helix. The structure also shows 
dimerization mediated over its HAT-CTDs. Interestingly however, it could be shown that 
only one copy RNA 15, one of the components of the cleavage factor IA, binds to the 
RNA14 dimer (Paulson and Tong 2012). 
Dimerization is not only observed for HAT repeat proteins but is an important part of many 
biological processes providing, for example, diversity and specificity, regulating gene 
expression and activity of enzymes (Hashimoto and Panchenko 2010). Oligomerization 
can help reducing the genome size, still allowing for large structure assemblies through 
modular complex formation. Additionally small protein subunits will fold more readily than 
a single large protein would (Jones and Thornton 1995, Goodsell and Olson 2000, 
Marianayagam 2004). The reduced surface area of oligomers compared to its monomers 
can also have a beneficial effect on protein stability, by protection against denaturation 
(Miller 1987). Homodimers are especially interesting cases. More than half of the 
oligomers observed are dimers, the bulk of the dimers being homodimers (Mei 2005). They 
occur more frequently than could be explained by random evolution and have 
approximately double as many interaction partners as proteins that do not interact with 
themselves (Ispolatov 2005). 
The simplest functionality of dimerization is as a general sensor for protein concentrations. 
If the required concentration is exceeded, dimerization can occur and can be a stimulus 
for enzymatic activation. Dimerization can also provide new intermolecular interfaces that 




In some cases asymmetry can be induced in homodimers by binding of an additional 
component (Swapna 2012). 
It is very interesting, that the crystal structure of mPRPF39 shows the protein to be 
arranged as a homodimer, because in the yeast system, the structurally relevant 
heterodimer of yPrp39 and yPrp42 observed in cryo-EM studies (Li 2017, Bai 2018, 
Plaschka 2018) shows a similar mode of dimerization over its C-terminus. 
The yPrp39/yPrp42 heterodimer is a crucial scaffolding subcomplex. It acts as a hub for 
multiple protein-protein interactions for example the contact between the U1 and the U2 
snRNP, indicating that the yPrp39/yPrp42 heterodimer is important for the precise spatial 
positioning of the snRNPs to each other. As a Prp42 homolog is unknown in metazoan, 
this suggests, that the PRPF39 homodimer could maybe functionally substitute the 
heterodimer observed in yeast. 
In crystal structures, proteins are arranged in a multimeric fashion very often, due to the 
nature of crystals. The smallest unit of the crystal is the asymmetric unit (ASU). The whole 
crystal is made up of the same ASU which can be rotated and translated according to the 
symmetry operators specific to the space group of the crystal. The crystal packing helps 
stabilize the crystal, leading to interactions within and between ASUs. These interactions 
are not always biologically relevant, as the ASU is not defined in a biological context 
(Valdar and Thornton 2001). Consequently, verifying the dimerization with other methods 
was indispensable. The fact that the dimerization can be seen in solution as well as in a 
cellular environment was a promising hint, that mPRPF39 could indeed substitute the 
heterodimer observed in yeast. 
The unstructured C-terminal domain of mPRPF39 seems to have stabilizing properties 
towards the homodimerization but is not sufficient to disrupt the dimer. Removing the CTD 
gives rise to a small amount of monomeric mPRPF39, to the dimeric protein and, in 
addition, to a peak with a disperse molecular weight distribution, most likely corresponding 
to multimeric aggregated mPRPF39. Most likely the mPRPF39 CTD is necessary for 
overall stabilization of the protein, fixing it in its preferred dimeric state. When looking at 
the structure of the yPrp39/yPrp42 the yPrp39 CTD binds across the concave side of the 
yPrp42 HAT-NTD. This supports the hypothesis of the CTD being important to stabilize 
the mPRPF39 homodimer with additional contacts if the mPRPF39 CTD assumes a similar 
fold. 
This thesis shows that the dimerization in mPRPF39 is mainly mediated by charged 
residues located in the concave face of the HAT-CTD. Mutation of just a single residue in 




completely abolish dimerization. Other homooligomers with complementarily charged 
patches mediating dimerization have been previously described in literature, e.g. the 
ryanodine receptor 1 (Lee and Allen 2007) and the ribonucleotide reductase small subunit 
M2 (Chen 2014). 
However, the yPrp39/yPrp42 dimerization is not based on charged residues at all. The 
only salt bridge is between the yPrp39 CTD and the yPrp42 HAT-NTD. To further compare 
the homodimer of mPrp39 and the heterodimer of yPrp39/ yPrp42 we used the cryo-EM 
structure of the U1 snRNP (Li 2017) and inspected protein-protein interactions as well as 
snRNA interactions.  
A detailed analysis based on the available structures as well as sequence conservation, 
revealed that mPRPF39 shows higher similarity both at the structural level as well as in 
amino acid conservation to yPrp42 than to yPrp39, indicating a misidentification of Prp42 
homologs as Prp39 homologs in higher eukaryotes. It is likely that Prp42 and Prp39 have 
emerged from the same ancestral gene by gene duplication rendering all Prp39 homologs 
at the same time also Prp42 homologs. Incidentally, an additional patch of sequence 
conservation in the HAT-CTD can be observed on the concave surface of the HAT-NTD 
of mPrp39. This is the same area on yPrp42 that mediates protein-protein contacts 
connecting the core U1 snRNP to its auxiliary proteins. The fact that this analog area is 
conserved in mPRPF39 supports the hypothesis that mPRPF39 is also a yPrp42 homolog 
and can substitute it in binding to the U1 snRNP via U1C. 
There are many proteins in the human spliceosome that do not have an obvious 
counterpart in yeast (Fabrizio 2009, Will and Luhrmann 2011). However, this is the 
opposite for PRPF39. In yeast the Prp39/Prp42 heterodimer is stably associated with the 
U1 snRNP. This is not the case in metazoan, with PRPF39 only transiently associated to 
the spliceosome. One of the main factors that allow for more stable binding of the 
heterodimer is the length of the U1 snRNA SL 2. The elongated SL that is absent in 
metazoa folds over and binds the charged surface of yPrp42. This interaction acts as a 
clamp that functions as an additional stabilizer to the binding of the heterodimer to the U1 
snRNP core which is otherwise mediated over interactions with the concave side of the 
yPrp42 HAT-NTD and yU1C. Not only is the elongated SL 2 missing in the metazoan 
system, but also the positively charged groove at the equivalent position to yPrp42 is 
missing in mPRPF39. This only leaves the interaction with U1C as a connector between 
the metazoan auxiliary U1 snRNP proteins to its core, posing a possible explanation for 




The more transient association of the homodimer to the spliceosome in the metazoan 
system could also serve as an explanation for the finding that the human pre-B complex 
structure shows no contacts between the U1 and U2 snRNP (Zhan 2018). Possibly the 
loosely associated homodimer can mediate inter-snRNP contacts during complex A 
formation. Due to its loose association it might allow for separation of the particles in the 
pre-B state, which may be important to encourage the more complex alternative splicing 
patterns observed in organisms with a Prp39 homodimer. Other splicing factors have also 
been reported to associate more transiently with the spliceosome in humans. For example, 
Prp38 and Snu23 are stable snRNP components in yeast but in human they enter the 
spliceosome individually after the tri-snRNP (Ulrich and Wahl 2017). SF3a and SF3b are 
another case of proteins that show weak binding to the U2 snRNP. Even though they are 
phylogenetically conserved they were initially not identified due to their weak association 
to the spliceosome (Kramer 1996). Both, this as well as the data presented here 
demonstrate a lower level of fixed pre-organization of metazoan spliceosomes versus 
yeast spliceosomes. 
In vitro splicing experiments with monomeric mPRPF39 show, that disruption of the dimer 
has a detrimental effect on splicing efficiency. In addition, supplementing splicing reactions 
with wild type mPRPF39, and thus changing the levels of functional PRPF39, show a trend 
toward higher splicing efficiency. This trend is not significant, the p value of 0.09 being just 
over the threshold of 0.05. It is not surprising that the effect of adding mPRPF39 to the 
reaction does not have a robust effect, because there is still endogenous PRPF39 in the 
used splicing nuclear extracts. mPRPF39 positively influences splicing efficiency, while 
monomeric mPRPF39 has an inhibitory effect. This is a further piece of evidence, that the 
mPRPF39 homodimer is the functional subunit and can substitute the yPrp39/yPrp42 
heterodimer observed in yeast in metazoans. 
 
8.2 Activation Dependent and Tissue Specific Regulation of 
mPRPF39 by a Combination of NMD and Production of Non-
functionally Truncated Protein Isoforms 
After seeing direct effects on splicing efficiency in vitro depending on the levels of 
functional mPRPF39, it was especially interesting to find, that the mPRPF39 RNA is 
alternatively spliced in a differential manner. The inclusion of the alternative exon is highly 
regulated by the T-cell differentiation state and different levels of inclusion can also be 




NMD target, making this exon a poison exon. Poison exons are a widespread mechanism 
used by organisms to control expression levels of proteins. For example SRSF3 regulates 
the inclusion of poison exons, strongly conserved among species (Lareau 2007), in itself 
and SRSF2, SRSF5 and SRSF7 (Anko 2012). 
Our experiments indicate, that the mprpf39 pre-mRNA is at best a weak NMD target. 
However, regardless of whether the inclusion isoform is degraded or translated, this 
isoform will lead to a reduced level of functional protein because the translated product 
would be missing the part of the HAT-CTD crucial for dimerization (Figure 46).  
 
Figure 46 PHYRE Structure prediction (Kelley 2015) of short mPRPF39 fragment arising from 
alternative splicing. The protein is shown in cartoon representation with coloring analog to Figure 
25. The short version of the mPRPF39 protein stops with an alternative amino acid sequence 
deriving from the alternative exon containing a stop codon that is included shown in red. The 
alternative sequence is also predicted to form α-helices. 
The resulting protein would have an intact HAT-NTD with a severely shortened HAT-CTD. 
This would still allow it to bind to the spliceosome, but act to suppress splicing, because it 
does now allow dimer formation. Interestingly the new additional amino acid residues 
stemming from the segment of the alternative exon before the stop codon, are predicted 
to form HAT repeat similar α-helices. This supports the hypothesis of a truncated 





Figure 47 Non-productive splicing of PRPF39. When constitutive splicing occurs, PRPF39 is 
generated and the homodimer allows splicing. When the alternative exon is included the prpf39 
pre-mRNA is either degraded leading to depletion of PRPF39 or to a truncated PRPF39. Both 
scenarios would lead to blocking of splicing. 
The fact that the function of the premature stop codon in the alternative exon is conserved 
in the human system cements the importance of this system to fine tune the Prpf39 levels 
in a tissue specific and differentiation dependent manner and suggests this as a 
mechanism across species. Together with its impact on splicing in vitro, this suggests a 
role of PRPF39 in adapting splicing efficiency to cell type specific requirements. The tightly 
controlled regulation of mPRPF39 protein levels is especially interesting, when seen in the 
context of dimerization. As already mentioned, one of the more basic mechanisms to 
regulate activity of dimeric proteins, is the concentration. This could explain, why 
maintaining exact levels of PRPF39 is crucial, because the dimerization could be 
dependent on the PRPF39 level rising above a certain threshold. Our data suggest a role 
of PRPF39 in adapting splicing efficiency to the requirements of specific cells or tissues. 
In particular in immune cell differentiation and activation it has been shown that regulated 
intron retention plays an important role in controlling gene expression and function (Ni 
2016). Controlling PRPF39 levels through inclusion of an exon containing a premature 
stop codon may contribute to fine tune splicing efficiency and intron retention in such 





8.3 Higher Splicing Complexity is Evolutionarily Connected to 
Reduced Amounts of Spliceosomal Components 
The investigation of the length of U1 snRNA in different organisms revealed that SL 2 and 
SL 3 are significantly shorter in metazoans compared to its yeast counterpart. This 
shortened U1 snRNA goes hand in hand with altered structural properties of mPRPF39. 
yPrp42 has a strongly positively charged groove on the convex side of the HAT-NTD that 
can accommodate the U1 snRNA. This positively charged groove is not detectable in the 
structure of mPRPF39. Strikingly, all of the organisms analyzed with a short U1 snRNA 
are also lacking a Prp42 homolog and consequently a homodimer of PRPF39 is the 
functional subunit in these organisms. Hence, I propose that a co-evolutionary mechanism 
based on the protein as well as on the RNA level has occurred. 
The correlation between the length of the U1snRNA and the loss of Prp42 with splicing 
complexity show that this evolutionary development was important to allow for more 
complex splicing. This could be because a system with lower pre-organization is more 
susceptible to regulation. In yeast, the yPrp39/yPrp42 heterodimer acts as a binding 
platform for multiple alternative splicing factors (Li 2017, Bai 2018, Plaschka 2018). In 
metazoan the transient association could enable an additional level of regulation, which 
suggests, that homodimeric PRPF39 could also have a role in enabling and regulating 
more complex alternative splicing.  
The analysis implies, that a short U1 snRNA SL 2 in a system without a Prp42 homolog 
acts to loosen the association of the dimer to the U1 snRNP core. This makes way for 
more complex regulation of association and disassociation of alternative splicing factors. 
 
8.4 mPRPF39 substitutes for the Yeast Heterodimer and Allows 
for More Complex Splicing in Metazoans in Conjuncture with 
a Short U1 snRNA 
Because the yPrp39/yPrp42 heterodimer seems to be so crucial in organizing the 
spliceosome during early splicing (Bai 2018, Plaschka 2018) it would be very surprising if 
there were no unit that could functionally substitute the heterodimer in the metazoan 
system.  
PRPF39 appears to be a likely candidate for this. It is present in a homodimeric form that 
shows high similarity to the heterodimer observed in yeast and monomerization has a 




controlled in a differentiation and tissue specific manner, highlighting the importance that 
mPRPF39 levels, especially in a dimeric form, have on splice efficiency. 
Furthermore, our analysis of the U1 snRNA length versus presence of a homodimer or a 
heterodimer, led us to an interesting conclusion: The reduced U1 snRNA length and the 
reduced protein content, achieved by replacing two different proteins with a single 
homodimeric protein, does not in fact reduce slicing complexity, but rather increases it 
(Figure 48). 
 
Figure 48 Increased versatility despite reduced molecular complexity. In this suggested model, the 
U1 snRNA SL 2 acts as a clamp to tightly bind the yPrp39/yPrp42 heterodimer to the U1 snRNP 
core. In metazoans, the missing extended SL 2 and the missing binding interface in PRPF39 lead 
to a more transient association of the dimer. This increases the possible layers of regulation. In 
yeast only the association and dissociation of additional splicing factors can be regulated, but in 
metazoans the whole homodimer interaction hub can be dissociated. 
These findings are in contrast to current models, in which an increasing protein decoration 
of the eukaryotic spliceosome is correlated with increasing splicing complexity. This study 




less complex splicing, but might actually be beneficial for highly regulated, sophisticated 
splicing. 
This work presents the first detailed structural and functional analysis of the essential 
splicing factor Prp39. It seems to be an important modulator of splicing, that is active in 
early spliceosome formation. It is a new building block that will be of great impact for future 
structure determination of spliceosomal assemblies by cryo-EM. It is also an interesting 
target for many more analyses of constitutive splicing and also alternative splicing. We 
supply an invaluable tool to further characterize PRPF39 and the impact of dimerization 
on splicing with our monomeric isoforms. 
 
8.5 Future Perspectives 
To allow for a broader analysis of the effect of PRPF39 on metazoan splicing, functional 
assays in a cellular environment would be beneficial. Studying protein functions in cells is 
greatly helped by loss of function experiments, in which a system is, for example, depleted 
of PRPF39. However, this is challenging for essential proteins. Completely knocking out 
PRPF39 would be lethal to the cell. When studying the role of an essential protein it is 
crucial to use a method that can conditionally deplete the system of this protein. Protein 
expression can be inhibited at the DNA, RNA or protein level. One method for reducing 
the amount of protein in a cell is a knock down with specific siRNAs. In our hands the use 
of six different siRNAs in every possible combination with varying cell seeding 
concentrations and harvesting after different time points after transfection never led to a 
substantial downregulation even on the RNA level. This indicates that a more sophisticated 
approach is necessary. 
One of the main drawbacks of conditional technologies working at the level of DNA or RNA 
is, that the time necessary for depletion of a protein is dependent on the said half-life 
because they work pre-translationally. To overcome this issue, a knock down on protein 
level could be employed. In the case of PRPF39 initial experiments hint, that the protein 
is stable in the cell over a long period of time. This makes a conditional knock down on the 
protein level especially attractive. 
One possible solution would be using a fusion protein with a degron. A degron is a domain 
which confers instability to a protein of interest which is then degraded by the 16S 
proteasome. Temperature, small molecules, light, or the expression of other additional 




2017). Some of the degron systems allow for exact regulation of the protein levels in the 
cell. 
To use a degron based technology, genetic modification is necessary to attach the degron 
sequence to the protein of interest. CRISPR-Cas9 based genome editing has opened up 
many possibilities but insertion of large DNA sequences can still represent a challenging 
and time-consuming process. An alternative approach would be to create a cell line stably 
expressing in this case a PRPF39-degron fusion protein. In a second step the endogenous 
PRPF39 could be knocked out with the CRISPR-Cas9 system, which is a much simpler 
process that is easier to screen for. 
If one had a cell system with an inducible PRPF39-degron fusion protein, a plethora of 
different assays could be used to analyze phenotypical differences between normal cells 
and knock down mutants. A very straightforward first experiment would be RNA 
sequencing of wild type cells or cells depleted of PRPF39. This should present us with 
information on the effect that PRPF39 has on overall splicing. Using cells depleted of 
PRPF39 would also allow us to analyze the effect of the monomeric PRPF39 without 
interference of endogenous wild type protein more readily. 
Another interesting open question is, how the alternative splicing event observed in 
mPRPF39 is regulated. Because the inclusion is differentially regulated in tissue specific 
manner, the regulation must come from trans-acting factors. The degron system could 
help us find out if PRPF39 self-regulates its poison exon. 
The experiments show that different levels of mPRPF39 have an effect on splicing in vitro 
and the protein level is controlled in a tissue and differentiation specific manner. Therefore, 
using a degron system could be used to tailor PRPF39 levels in cells which could then be 
harvested and analyzed. 
The yeast early spliceosome structures show various alternative splicing factors 
associated with the yPrp39/yPrp42 heterodimer (Li 2017, Bai 2018, Plaschka 2018). It 
remains an open question, if these factors will also use the PRPF39 homodimer as an 
interaction hub in the metazoan system. Furthermore, it would be interesting to analyze 
whether the dimerization has an influence on binding of the proteins. The monomeric 
mutants are a powerful tool to use in determining the influence of dimerization on protein 
association. Mass spectrometry analyses using monomeric and dimeric PRPF39 could be 
used for this purpose. 
In this thesis it is hypothesized, that a short U1 snRNA SL 2 in combination with a 
homodimeric PRPF39 allows for more complex splicing. An interesting approach to show 




metazoan system and a positive patch in metazoan PRPF39 HAT-NTD equivalent to the 
one seen in yPrp42. The new longer U1 snRNA would then hopefully clamp the otherwise 
more transiently associated homodimer to the U1 snRNP. If this hypothesis is correct, 
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